Fabien Zoulim
#102,319
Most Influential Person Now
Researcher
Fabien Zoulim's AcademicInfluence.com Rankings
Fabien Zoulimbiology Degrees
Biology
#5187
World Rank
#7611
Historical Rank
Virology
#97
World Rank
#100
Historical Rank
Molecular Biology
#449
World Rank
#458
Historical Rank
Biochemistry
#592
World Rank
#682
Historical Rank
Download Badge
Biology
Why Is Fabien Zoulim Influential?
(Suggest an Edit or Addition)Fabien Zoulim's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. (2017) (2984)
- EASL Clinical Practice Guidelines: management of chronic hepatitis B. (2009) (1471)
- A new genotype of hepatitis B virus: complete genome and phylogenetic relatedness. (2000) (959)
- Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. (2004) (838)
- Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseases (2013) (826)
- Statements from the Taormina expert meeting on occult hepatitis B virus infection. (2008) (784)
- Hepatitis B virus resistance to nucleos(t)ide analogues. (2009) (676)
- Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial (2019) (620)
- Antiviral drug‐resistant HBV: Standardization of nomenclature and assays and recommendations for management (2007) (474)
- Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890. (2013) (449)
- Impaired allostimulatory function of dendritic cells in chronic hepatitis C infection. (2001) (448)
- Woodchuck hepatitis virus X protein is required for viral infection in vivo (1994) (441)
- Eradication of Hepatitis C Virus Infection in Patients With Cirrhosis Reduces Risk of Liver and Non-Liver Complications. (2017) (403)
- Hepatitis B virus X protein is essential to initiate and maintain virus replication after infection. (2011) (373)
- Hepatic encephalopathy in chronic liver disease: 2014 practice guideline by the European Association for the Study of the Liver and the American Association for the Study of Liver Diseases. (2014) (371)
- Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study (2019) (343)
- Meta-analyses of FibroTest diagnostic value in chronic liver disease (2007) (320)
- Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient. (2003) (306)
- Mitochondria-Associated Endoplasmic Reticulum Membrane (MAM) Integrity Is Required for Insulin Signaling and Is Implicated in Hepatic Insulin Resistance (2014) (287)
- Update of the statements on biology and clinical impact of occult hepatitis b virus infection. (2019) (285)
- A Placebo‐Controlled Trial of Bezafibrate in Primary Biliary Cholangitis (2018) (283)
- Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir (2005) (283)
- Therapeutic strategies for hepatitis B virus infection: towards a cure (2019) (281)
- Hepatitis B virus genetic variability and evolution. (2007) (278)
- Report of an international workshop: Roadmap for management of patients receiving oral therapy for chronic hepatitis B. (2007) (276)
- Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis. (2014) (272)
- Hepatitis B cure: From discovery to regulatory approval. (2017) (263)
- Present and future therapies of hepatitis B: From discovery to cure (2015) (259)
- Comparison of 1 or 3 MU of interferon alfa-2b and placebo in patients with chronic non-A, non-B hepatitis. (1991) (258)
- Genome Replication, Virion Secretion, and e Antigen Expression of Naturally Occurring Hepatitis B Virus Core Promoter Mutants (2003) (257)
- Reverse transcription in hepatitis B viruses is primed by a tyrosine residue of the polymerase (1994) (256)
- Management of Antiviral Resistance in Patients with Chronic Hepatitis B (2004) (253)
- A global scientific strategy to cure hepatitis B. (2019) (253)
- Virologic monitoring of hepatitis B virus therapy in clinical trials and practice: recommendations for a standardized approach. (2008) (244)
- Towards an HBV cure: state-of-the-art and unresolved questions—report of the ANRS workshop on HBV cure (2015) (241)
- Strategies to inhibit entry of HBV and HDV into hepatocytes. (2014) (238)
- New insight on hepatitis B virus persistence from the study of intrahepatic viral cccDNA. (2005) (237)
- Rapid detection of genotypes and mutations in the pre-core promoter and the pre-core region of hepatitis B virus genome: correlation with viral persistence and disease severity. (2000) (236)
- Hepatitis B virus induced hepatocellular carcinoma. (2009) (234)
- Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B (2000) (220)
- Impact of hepatitis B virus rtA181V/T mutants on hepatitis B treatment failure. (2008) (201)
- Selection of a multiple drug-resistant hepatitis B virus strain in a liver-transplanted patient. (2006) (189)
- The way forward in HCV treatment — finding the right path (2008) (187)
- Entecavir treatment does not eliminate the risk of hepatocellular carcinoma in chronic hepatitis B: limited role for risk scores in Caucasians (2014) (187)
- Line Probe Assay for Monitoring Drug Resistance in Hepatitis B Virus-Infected Patients during Antiviral Therapy (2000) (182)
- Mechanism of viral persistence and resistance to nucleoside and nucleotide analogs in chronic hepatitis B virus infection. (2004) (180)
- Serum hepatitis B core-related antigen (HBcrAg) correlates with covalently closed circular DNA transcriptional activity in chronic hepatitis B patients. (2019) (178)
- New antiviral targets for innovative treatment concepts for hepatitis B virus and hepatitis delta virus. (2016) (177)
- Hepatitis B: reflections on the current approach to antiviral therapy. (2008) (175)
- High incidence of hepatitis B infections among chronic hepatitis cases of unknown aetiology. (2001) (175)
- Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis (2012) (174)
- Care of HIV patients with chronic hepatitis B: updated recommendations from the HIV-Hepatitis B Virus International Panel. (2008) (172)
- Incidence of Hepatocellular Carcinoma After Direct Antiviral Therapy for HCV in Patients With Cirrhosis Included in Surveillance Programs. (2018) (170)
- Aberrant DNA methylation distinguishes hepatocellular carcinoma associated with HBV and HCV infection and alcohol intake. (2011) (168)
- Entecavir treatment for chronic hepatitis B: Adaptation is not needed for the majority of naïve patients with a partial virological response (2011) (167)
- Hepatitis B cure: From discovery to regulatory approval (2017) (166)
- Monitoring Drug Resistance in Chronic Hepatitis B Virus (HBV)-Infected Patients during Lamivudine Therapy: Evaluation of Performance of INNO-LiPA HBV DR Assay (2002) (164)
- Stepwise process for the development of entecavir resistance in a chronic hepatitis B virus infected patient. (2007) (164)
- Long term histological improvement and clearance of intrahepatic hepatitis C virus RNA following sustained response to interferon-ribavirin combination therapy in liver transplanted patients with hepatitis C virus recurrence (2003) (161)
- Molecular Genetics of HBV Infection (2010) (161)
- Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS). (2015) (157)
- HBVdb: a knowledge database for Hepatitis B Virus (2012) (154)
- Tenofovir is effective alone or with emtricitabine in adefovir-treated patients with chronic-hepatitis B virus infection. (2010) (147)
- Receptor Complementation and Mutagenesis Reveal SR-BI as an Essential HCV Entry Factor and Functionally Imply Its Intra- and Extra-Cellular Domains (2009) (145)
- Hepatitis B Virus Impairs TLR9 Expression and Function in Plasmacytoid Dendritic Cells (2011) (142)
- Antiviral therapies and prospects for a cure of chronic hepatitis B. (2015) (142)
- Control of hepatitis B virus replication by innate response of HepaRG cells (2010) (140)
- Hepatitis C virus-induced hepatocarcinogenesis. (2009) (137)
- Longitudinal Assessment of Histology Surrogate Markers (FibroTest–ActiTest) During Lamivudine Therapy in Patients with Chronic Hepatitis B Infection (2005) (135)
- Selection of chronic hepatitis B therapy with high barrier to resistance. (2012) (133)
- Hepatitis C virus treatment in the real world: optimising treatment and access to therapies (2015) (133)
- Persistence of the hepatitis B virus covalently closed circular DNA in HepaRG human hepatocyte-like cells. (2009) (133)
- Global strategies are required to cure and eliminate HBV infection (2016) (132)
- Efficacy of the protease inhibitor BI 201335, polymerase inhibitor BI 207127, and ribavirin in patients with chronic HCV infection. (2011) (131)
- Analysis of hepatitis B virus genotypes and pre‐core region variability during interferon treatment of HBe antigen negative chronic hepatitis B (1996) (131)
- Role of RNA in enzymatic activity of the reverse transcriptase of hepatitis B viruses (1994) (130)
- The way forward in HCV treatment — finding the right path (2007) (127)
- Entecavir plus tenofovir combination as rescue therapy in pre-treated chronic hepatitis B patients: an international multicenter cohort study. (2012) (125)
- Mutations affecting the replication capacity of the hepatitis B virus (2006) (125)
- Guidance for Design and Endpoints of Clinical Trials in Chronic Hepatitis B—Report From the 2019 EASL‐AASLD HBV Treatment Endpoints Conference (2019) (122)
- Guidance for Design and Endpoints of Clinical Trials in Chronic Hepatitis B—Report From the 2019 EASL‐AASLD HBV Treatment Endpoints Conference (2019) (122)
- Hepatitis B virus resistance to antiviral drugs: where are we going? (2011) (121)
- Management of treatment failure in chronic hepatitis B. (2012) (121)
- Antiviral effect of entecavir in chronic hepatitis B: influence of prior exposure to nucleos(t)ide analogues. (2010) (118)
- Statins potentiate the in vitro anti‐hepatitis C virus activity of selective hepatitis C virus inhibitors and delay or prevent resistance development (2009) (118)
- Preferential association of Hepatitis C virus with apolipoprotein B48-containing lipoproteins. (2006) (117)
- Major role of hepatitis B genotypes in liver fibrosis during coinfection with HIV (2006) (115)
- How viral genetic variants and genotypes influence disease and treatment outcome of chronic hepatitis B. Time for an individualised approach? (2017) (114)
- Inhibitory activity of dioxolane purine analogs on wild‐type and lamivudine‐resistant mutants of hepadnaviruses (2002) (113)
- Early inhibition of hepatocyte innate responses by hepatitis B virus. (2015) (113)
- Clinical consequences of hepatitis C virus infection (2003) (110)
- Gut roundtable meeting paper: selected recent advances in hepatocellular carcinoma (2017) (109)
- Drug therapy for chronic hepatitis B: antiviral efficacy and influence of hepatitis B virus polymerase mutations on the outcome of therapy. (1998) (108)
- A new strategy for studying In Vitro the drug susceptibility of clinical isolates of human hepatitis B virus (2004) (106)
- Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference. (2019) (106)
- Transient selection of a hepatitis B virus polymerase gene mutant associated with a decreased replication capacity and famciclovir resistance (1999) (105)
- Why are there different dynamics in the selection of drug resistance in HIV and hepatitis B and C viruses? (2008) (105)
- Intrahepatic innate immune response pathways are downregulated in untreated chronic hepatitis B. (2017) (104)
- Occult HBV infection may represent a major risk factor of non‐response to antiviral therapy of chronic hepatitis C (2007) (104)
- Long-term hepatitis B virus dynamics in HIV–hepatitis B virus-co-infected patients treated with tenofovir disoproxil fumarate (2005) (104)
- Homozygous MTTP and APOB mutations may lead to hepatic steatosis and fibrosis despite metabolic differences in congenital hypocholesterolemia. (2014) (103)
- Benefit of Sustained Virological Response to Combination Therapy on Graft Survival of Liver Transplanted Patients with Recurrent Chronic Hepatitis C (2005) (102)
- Safety and efficacy of daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patients. (2017) (100)
- Reasons to consider earlier treatment of chronic HBV infections (2011) (98)
- Disruption of calcium transfer from ER to mitochondria links alterations of mitochondria-associated ER membrane integrity to hepatic insulin resistance (2016) (97)
- Identification of a quadruple mutation that confers tenofovir resistance in chronic hepatitis B patients. (2019) (96)
- Complications and competing risks of death in compensated viral cirrhosis (ANRS CO12 CirVir prospective cohort) (2015) (95)
- 8 SAFETY OF TELAPREVIR OR BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA/RIBAVIRIN, IN CIRRHOTIC NON RESPONDERS. FIRST RESULTS OF THE FRENCH EARLY ACCESS PROGRAM (ANRS CO20-CUPIC) (2012) (93)
- Risk of hepatitis B surface antigen seroreversion after allogeneic hematopoietic SCT (2011) (93)
- Efficacy and safety of simeprevir with PegIFN/ribavirin in naïve or experienced patients infected with chronic HCV genotype 4. (2015) (90)
- Cloning and expression of surface antigens from occult chronic hepatitis B virus infections and their recognition by commercial detection assays (2004) (90)
- Altered expression profiles of microRNAs in a stable hepatitis B virus-expressing cell line. (2009) (88)
- Validation of Baveno VI Criteria for Screening and Surveillance of Esophageal Varices in Patients With Compensated Cirrhosis and a Sustained Response to Antiviral Therapy. (2019) (87)
- Sequential treatment with lamivudine and interferon monotherapies in patients with chronic hepatitis B not responding to interferon alone: Results of a pilot study (2001) (87)
- Progress towards elimination goals for viral hepatitis (2020) (86)
- Inhibitory Effect of Adefovir on Viral DNA Synthesis and Covalently Closed Circular DNA Formation in Duck Hepatitis B Virus-Infected Hepatocytes In Vivo and In Vitro (2002) (85)
- Decay of ccc-DNA marks persistence of intrahepatic viral DNA synthesis under tenofovir in HIV-HBV co-infected patients. (2016) (85)
- Etanercept treatment for three months is safe in patients with rheumatological manifestations associated with hepatitis C virus. (2007) (84)
- Hepatitis B virus genotype and basal core promoter/precore mutations are associated with hepatitis B-related acute-on-chronic liver failure without pre-existing liver cirrhosis (2010) (84)
- Evolution of hepatitis B virus polymerase gene sequence during famciclovir therapy for chronic hepatitis B. (2000) (80)
- Pharmacological inhibition of Frizzled-7 displays anti-tumor properties in hepatocellular carcinoma. (2011) (80)
- Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open- (2017) (79)
- Long-term efficacy and safety of emtricitabine plus tenofovir DF vs. tenofovir DF monotherapy in adefovir-experienced chronic hepatitis B patients. (2014) (78)
- Simeprevir versus telaprevir with peginterferon and ribavirin in previous null or partial responders with chronic hepatitis C virus genotype 1 infection (ATTAIN): a randomised, double-blind, non-inferiority phase 3 trial. (2015) (77)
- Nomogram for individualized prediction of hepatocellular carcinoma occurrence in hepatitis C virus cirrhosis (ANRS CO12 CirVir) (2016) (76)
- N-glycosylation mutations within hepatitis B virus surface major hydrophilic region contribute mostly to immune escape. (2014) (76)
- The main hepatitis B virus (HBV) mutants resistant to nucleoside analogs are susceptible in vitro to non-nucleoside inhibitors of HBV replication. (2011) (76)
- Impact of highly active antiretroviral therapy (HAART) on the natural history of hepatitis B virus (HBV) and HIV coinfection: relationship between prolonged efficacy of HAART and HBV surface and early antigen seroconversion. (2007) (76)
- Daclatasvir plus sofosbuvir, with or without ribavirin, for hepatitis C virus genotype 3 in a French early access programme (2017) (75)
- Characterization of the Antiviral Effect of 2′,3′-Dideoxy-2′, 3′-Didehydro-β-l-5-Fluorocytidine in the Duck Hepatitis B Virus Infection Model (2000) (74)
- In vitro characterization of viral fitness of therapy-resistant hepatitis B variants. (2009) (73)
- A prospective study of the evolution of lamivudine resistance mutations in patients with chronic hepatitis B treated with lamivudine (2006) (71)
- Ribavirin monotherapy in patients with chronic hepatitis C: a retrospective study of 95 patients (1998) (70)
- Compliance With Hepatocellular Carcinoma Surveillance Guidelines Associated With Increased Lead-Time Adjusted Survival of Patients With Compensated Viral Cirrhosis: A Multi-Center Cohort Study. (2018) (69)
- Treatment of hepatitis B virus-infected cells with alpha-glucosidase inhibitors results in production of virions with altered molecular composition and infectivity. (2007) (69)
- Toll-like receptor 7 agonist GS-9620 induces prolonged inhibition of HBV via a type I interferon-dependent mechanism. (2017) (68)
- Persistent viremia in human immunodeficiency virus/hepatitis B coinfected patients undergoing long‐term tenofovir: Virological and clinical implications (2014) (68)
- Hepatitis B virus X protein stimulates gene expression selectively from extrachromosomal DNA templates (2012) (67)
- Current treatments for chronic hepatitis B virus infections. (2016) (66)
- Novel Potent Capsid Assembly Modulators Regulate Multiple Steps of the Hepatitis B Virus Life Cycle (2018) (66)
- Hepatitis B virus: from diagnosis to treatment. (2010) (65)
- Intrafamilial prevalence of hepatitis B virus in Western Brazilian Amazon region: Epidemiologic and biomolecular study (2006) (65)
- Association of hepatitis B virus mutations in basal core promoter and precore regions with severity of liver disease: an investigation of 793 Chinese patients with mild and severe chronic hepatitis B and acute-on-chronic liver failure (2010) (65)
- Selection of Hepatitis B Virus (HBV) Vaccine Escape Mutants in HBV-Infected and HBV/HIV-Coinfected Patients Failing Antiretroviral Drugs With Anti-HBV Activity (2007) (65)
- Recent advances in alcohol-related liver disease (ALD): summary of a Gut round table meeting (2019) (64)
- Innate Antiviral Immune Responses to Hepatitis B Virus (2010) (64)
- DNA methylation of hepatitis B virus (HBV) genome associated with the development of hepatocellular carcinoma and occult HBV infection. (2010) (63)
- Quantification of HBsAg in nucleos(t)ide-naïve patients treated for chronic hepatitis B with entecavir with or without tenofovir in the BE-LOW study. (2015) (63)
- The diverse functions of the hepatitis B core/capsid protein (HBc) in the viral life cycle: Implications for the development of HBc-targeting antivirals. (2018) (63)
- Novel targets for hepatitis B virus therapy (2017) (63)
- Optimal management of chronic hepatitis B patients with treatment failure and antiviral drug resistance (2013) (63)
- HDV RNA replication is associated with HBV repression and interferon-stimulated genes induction in super-infected hepatocytes. (2016) (63)
- Sustained virologic response to direct-acting antiviral therapy in patients with chronic hepatitis C and hepatocellular carcinoma: A systematic review and meta-analysis. (2019) (63)
- Inhibitory Effect of 2′-Fluoro-5-Methyl-β-l-Arabinofuranosyl-Uracil on Duck Hepatitis B Virus Replication (1998) (63)
- Synthesis of 1,2,3-triazolo-carbanucleoside analogues of ribavirin targeting an HCV in replicon. (2003) (62)
- jpHMM: recombination analysis in viruses with circular genomes such as the hepatitis B virus (2012) (62)
- Effectiveness and Safety of Tenofovir Disoproxil Fumarate in Chronic Hepatitis B: A 3-Year, Prospective, Real-World Study in France (2016) (62)
- Expression and functionality of Toll- and RIG-like receptors in HepaRG cells. (2015) (62)
- Persistence of viral replication after anti-HBe seroconversion during antiviral therapy for chronic hepatitis B. (2000) (61)
- Rheumatological manifestations of hepatitis C: incidence in a rheumatology and non-rheumatology setting and the effect of methotrexate and interferon. (2005) (61)
- A research agenda for curing chronic hepatitis B virus infection (2018) (61)
- Characterization of two hepatitis B virus populations isolated from a hepatitis B surface antigen–negative patient (2002) (61)
- Direct‐acting antiviral therapy decreases hepatocellular carcinoma recurrence rate in cirrhotic patients with chronic hepatitis C (2017) (61)
- JNJ-56136379, an HBV Capsid Assembly Modulator, is Well-Tolerated and Has Antiviral Activity in a Phase 1 Study of Patients with Chronic Infection. (2020) (60)
- Detection of hepatitis B virus resistance to antivirals. (2001) (60)
- LONG-TERM FOLLOW-UP OF PATIENTS WITH CHRONIC HEPATITIS C TREATED WITH TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN: INTERIM ANALYSIS OF THE EXTEND STUDY (2010) (59)
- RNA helicase DEAD box protein 5 regulates Polycomb repressive complex 2/Hox transcript antisense intergenic RNA function in hepatitis B virus infection and hepatocarcinogenesis (2016) (59)
- Antiviral activity of various interferons and pro-inflammatory cytokines in non-transformed cultured hepatocytes infected with hepatitis B virus. (2016) (59)
- The negative impact of HBV/HCV coinfection on cirrhosis and its consequences (2017) (59)
- Antiviral Therapy of Chronic Hepatitis B: Can We Clear the Virus and Prevent Drug Resistance? (2004) (58)
- Genotypic resistance profile of hepatitis B virus (HBV) in a large cohort of nucleos(t)ide analogue‐experienced Chinese patients with chronic HBV infection (2010) (58)
- Rolling Circle Amplification, a Powerful Tool for Genetic and Functional Studies of Complete Hepatitis B Virus Genomes from Low-Level Infections and for Directly Probing Covalently Closed Circular DNA (2008) (57)
- Antiviral therapy of chronic hepatitis B. (2006) (56)
- Reduction of the infectivity of hepatitis C virus pseudoparticles by incorporation of misfolded glycoproteins induced by glucosidase inhibitors. (2007) (56)
- HBV cure: why, how, when? (2016) (55)
- Rapid detection and further characterization of infection with hepatitis B virus variants containing a stop codon in the distal pre-C region. (1990) (55)
- Direct antiviral properties of TLR ligands against HBV replication in immune-competent hepatocytes (2018) (54)
- Proficiency of transient elastography compared to liver biopsy for the assessment of fibrosis in HIV/HBV‐coinfected patients (2011) (54)
- Hepatitis B Virus e Antigen Loss during Adefovir Dipivoxil Therapy Is Associated with Enhanced Virus-Specific CD4+ T-Cell Reactivity (2007) (54)
- Progress in DNA vaccine for prophylaxis and therapy of hepatitis B. (2003) (54)
- High plasma level of nucleocapsid‐free envelope glycoprotein‐positive lipoproteins in hepatitis C patients (2012) (54)
- 2',3'-dideoxy-beta-L-5-fluorocytidine inhibits duck hepatitis B virus reverse transcription and suppresses viral DNA synthesis in hepatocytes, both in vitro and in vivo (1996) (54)
- Bacterial infection in compensated viral cirrhosis impairs 5-year survival (ANRS CO12 CirVir prospective cohort) (2015) (53)
- Polo‐like‐kinase 1 is a proviral host factor for hepatitis B virus replication (2017) (53)
- Hepatitis B genotypes/subgenotypes and MHR variants among Moroccan chronic carriers. (2011) (52)
- In vitro models for studying hepatitis B virus drug resistance. (2006) (52)
- Glucosidase inhibitors as antiviral agents for hepatitis B and C. (2007) (52)
- Endorsement of the Kidney Disease Improving Global Outcomes (KDIGO) hepatitis C guidelines: a European Renal Best Practice (ERBP) position statement. (2008) (51)
- Effects of Pyrimidine and Purine Analog Combinations in the Duck Hepatitis B Virus Infection Model (2003) (51)
- Increased body iron stores in elite road cyclists. (2002) (51)
- A novel hepatitis B virus mutation with resistance to adefovir but not to tenofovir in an HIV–hepatitis B virus-co-infected patient (2006) (50)
- Detection of the hepatitis B virus (HBV) covalently-closed-circular DNA (cccDNA) in mice transduced with a recombinant AAV-HBV vector. (2017) (50)
- Antiviral‐resistant hepatitis B virus: can we prevent this monster from growing? (2007) (50)
- Immune-modulators to combat hepatitis B virus infection: From IFN-α to novel investigational immunotherapeutic strategies. (2015) (50)
- Suboptimal Response to Adefovir Dipivoxil Therapy for Chronic Hepatitis B in Nucleoside-Naive Patients is not due to Pre-Existing Drug-Resistant Mutants (2008) (49)
- Genome-wide identification of direct HBx genomic targets (2017) (49)
- Antiviral effect of alpha-glucosidase inhibitors on viral morphogenesis and binding properties of hepatitis C virus-like particles. (2006) (49)
- New HBV subgenotype D9, a novel D/C recombinant, identified in patients with chronic HBeAg‐negative infection in Eastern India (2013) (49)
- Protease inhibitor‐based triple therapy in chronic hepatitis C: guidelines by the French Association for the Study of the Liver (2012) (49)
- European Multicenter Evaluation of High-Density DNA Probe Arrays for Detection of Hepatitis B Virus Resistance Mutations and Identification of Genotypes (2006) (49)
- LP05 : Daclatasvir plus sofosbuvir with or without ribavirin in patients with HCV genotype 3 infection: Interim analysis of a french multicenter compassionate use program (2015) (48)
- Resistance of human hepatitis B virus to reverse transcriptase inhibitors: from genotypic to phenotypic testing. (2005) (47)
- Kinetics of hepatitis B surface and envelope antigen and prediction of treatment response to tenofovir in antiretroviral-experienced HIV–hepatitis B virus-infected patients (2012) (47)
- Characterization of a New Sensitive PCR Assay for Quantification of Viral DNA Isolated from Patients with Hepatitis B Virus Infections (2007) (47)
- Initiation of hepatitis B virus genome replication and production of infectious virus following delivery in HepG2 cells by novel recombinant baculovirus vector. (2008) (47)
- Prognostic value of viral eradication for major adverse cardiovascular events in hepatitis C cirrhotic patients (2018) (47)
- Retreatment With Sofosbuvir Plus Grazoprevir/Elbasvir Plus Ribavirin of Patients With Hepatitis C Virus Genotype 1 or 4 Who Previously Failed an NS5A- or NS3-Containing Regimen: The ANRS HC34 REVENGE Study (2018) (47)
- Hepatitis B Virus-induced modulation of liver macrophage function promotes hepatocyte infection. (2019) (46)
- Antiviral Activity of β-l-2′,3′-Dideoxy-2′,3′-Didehydro-5-Fluorocytidine in Woodchucks Chronically Infected with Woodchuck Hepatitis Virus (2001) (46)
- Can we cure hepatitis B virus with novel direct‐acting antivirals? (2020) (45)
- RNA helicase DDX5 regulates PRC2/HOTAIR function in Hepatitis B Virus infection and hepatocarcinogenesis (2016) (45)
- Hepatitis C virus infection triggers a tumor‐like glutamine metabolism (2017) (44)
- Antiviral therapy of chronic hepatitis B: prevention of drug resistance. (2007) (44)
- Evolution of hepatitis B viral load and viral genome sequence during adefovir dipivoxil therapy (2004) (44)
- Evolution of hepatitis C virus genome in chronically infected patients receiving ribavirin monotherapy (2001) (43)
- Are novel combination therapies needed for chronic hepatitis B? (2012) (43)
- Inhibitory Effect of Penciclovir-Triphosphate on Duck Hepatitis B Virus Reverse Transcription (1997) (43)
- Analysis of HCV co-infection with occult hepatitis B virus in patients undergoing IFN therapy. (2005) (43)
- The role of nucleoside and nucleotide analogues in nodular regenerative hyperplasia in HIV-infected patients: a case control study. (2011) (43)
- Variable expression of preS1 antigen in serum during chronic hepatitis B virus infection: An accurate marker for the level of hepatitis B virus replication (1990) (43)
- Antiviral effect of adefovir in combination with a DNA vaccine in the duck hepatitis B virus infection model. (2003) (43)
- In Vitro Activity of 2,4-Diamino-6-[2-(Phosphonomethoxy)Ethoxy]-Pyrimidine against Multidrug-Resistant Hepatitis B Virus Mutants (2007) (42)
- Sustained HBs seroconversion during lamivudine and adefovir dipivoxil combination therapy for lamivudine failure. (2005) (42)
- Therapy of chronic hepatitis B virus infection: inhibition of the viral polymerase and other antiviral strategies. (1999) (42)
- Chronic Hepatitis B Virus Infection: Disease Revisit and Management Recommendations. (2016) (42)
- A 2-year multicenter, double-blind, randomized, placebo-controlled study of bezafibrate for the treatment of primary biliary cholangitis in patients with inadequate biochemical response to ursodeoxycholic acid therapy (Bezurso) (2017) (42)
- Different forms of hepatitis B virus DNA and expression of HBV antigens in peripheral blood mononuclear cells in chronic hepatitis B (1990) (42)
- Origin, HDV genotype and persistent viremia determine outcome and treatment response in patients with chronic hepatitis Delta. (2020) (42)
- Safety and immunogenicity of the therapeutic vaccine TG1050 in chronic hepatitis B patients: a phase 1b placebo-controlled trial (2019) (41)
- Entecavir: a new treatment option for chronic hepatitis B. (2006) (40)
- Prevalence of renal abnormalities in chronic HBV infection: The HARPE study (2015) (40)
- High incidence of treatment‐induced and vaccine‐escape hepatitis B virus mutants among human immunodeficiency virus/hepatitis B–infected patients (2013) (40)
- Glutathione peroxidase 4 is reversibly induced by HCV to control lipid peroxidation and to increase virion infectivity (2014) (40)
- Current hepatitis delta virus type 1 (HDV1) infections in central and eastern Turkey indicate a wide genetic diversity that is probably linked to different HDV1 origins (2012) (39)
- CD8+T cells from patients with cirrhosis display a phenotype that may contribute to cirrhosis-associated immune dysfunction (2019) (39)
- Viral and immune factors associated with successful treatment withdrawal in HBeAg-negative chronic hepatitis B patients (2020) (39)
- Clearance of serum HBsAg and anti‐HBs seroconversion following antiviral therapy for chronic hepatitis B (2009) (39)
- 60 SVR12 RATES AND SAFETY OF TRIPLE THERAPY INCLUDING TELAPREVIR OR BOCEPREVIR IN 221 CIRRHOTIC NON RESPONDERS TREATED IN THE FRENCH EARLY ACCESS PROGRAM (ANRS CO20-CUPIC) (2013) (38)
- Genetic variability of hepatitis C virus in chronically infected patients with viral breakthrough during interferon–ribavirin therapy (2004) (38)
- New nucleic acid diagnostic tests in viral hepatitis. (2006) (38)
- New assays for quantitative determination of viral markers in management of chronic hepatitis B virus infection (1992) (38)
- Very-Low-Density Lipoprotein (VLDL)-Producing and Hepatitis C Virus-Replicating HepG2 Cells Secrete No More Lipoviroparticles than VLDL-Deficient Huh7.5 Cells (2013) (38)
- Innate response to hepatitis B virus infection: Observations challenging the concept of a stealth virus (2009) (38)
- LO3 : Safety and efficacy of the combination daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patients from the french observational cohort ANRS CO22 hepather* (2015) (38)
- Management and prevention of drug resistance in chronic hepatitis B (2009) (38)
- Hepatitis A outbreak in HIV-infected MSM and in PrEP-using MSM despite a high level of immunity, Lyon, France, January to June 2017 (2017) (37)
- PREDICTION OF SUSTAINED RESPONSE AFTER NUCLEO(S)TIDE ANALOGUE CESSATION USING HBSAG AND HBCRAG LEVELS - A MULTICENTER STUDY (CREATE). (2020) (37)
- Clinical relevance of the study of hepatitis B virus covalently closed circular DNA (2016) (37)
- Perspectives and limitations for nucleo(t)side analogs in future HBV therapies. (2018) (37)
- New challenges in viral hepatitis (2012) (37)
- Variability in the Precore and Core Promoter Regions of HBV Strains in Morocco: Characterization and Impact on Liver Disease Progression (2012) (37)
- Personalized surveillance for hepatocellular carcinoma in cirrhosis - using machine learning adapted to HCV status. (2020) (36)
- Duck hepatitis B virus polymerase gene mutants associated with resistance to lamivudine have a decreased replication capacity in vitro and in vivo. (2001) (36)
- Rates and determinants of hepatitis B ‘e’ antigen and hepatitis B surface antigen seroclearance during long-term follow-up of patients coinfected with HIV and hepatitis B virus (2015) (36)
- Higher Mortality Despite Early Antiretroviral Therapy in Human Immunodeficiency Virus and Hepatitis B Virus (HBV)–Coinfected Patients With High HBV Replication (2018) (36)
- Effect of a Combination of Clevudine and Emtricitabine with Adenovirus-Mediated Delivery of Gamma Interferon in the Woodchuck Model of Hepatitis B Virus Infection (2004) (35)
- Critical Role of the 36-Nucleotide Insertion in Hepatitis B Virus Genotype G in Core Protein Expression, Genome Replication, and Virion Secretion (2007) (35)
- Characterization of Pattern Recognition Receptor Expression and Functionality in Liver Primary Cells and Derived Cell Lines (2018) (34)
- Plasmacytoid dendritic cells induce efficient stimulation of antiviral immunity in the context of chronic hepatitis B virus infection (2012) (34)
- Full-length 5'RACE identifies all major HBV transcripts in HBV-infected hepatocytes and patient serum. (2020) (34)
- Sequence-specific inhibition of duck hepatitis B virus reverse transcription by peptide nucleic acids (PNA). (2005) (34)
- Durability of Hepatitis B Surface Antigen Loss With Nucleotide Analogue and Peginterferon Therapy in Patients With Chronic Hepatitis B (2019) (34)
- Faldaprevir (Bi 201335), Deleobuvir (Bi 207127) and Ribavirin Oral Therapy for Treatment-Naive HCV Genotype 1: Sound-C1 Final Results (2013) (34)
- Woodchuck hepatitis virus-induced carcinoma as a relevant natural model for therapy of human hepatoma. (1997) (33)
- Non-invasive biomarkers for chronic hepatitis B virus infection management. (2019) (33)
- Management of patients with decompensated hepatitis B virus associated cirrhosis (2008) (33)
- A quasi-monoclonal anti-HBs response can lead to immune escape of 'wild-type' hepatitis B virus. (2005) (33)
- P1319 ONCE-DAILY SIMEPREVIR (TMC435) WITH PEGINTERFERON/RIBAVIRIN IN TREATMENT-NAIVE OR TREATMENT-EXPERIENCED CHRONIC HCV GENOTYPE 4-INFECTED PATIENTS: FINAL RESULTS OF A PHASE III TRIAL (2014) (32)
- Correlation between HBV DNA detection by polymerase chain reaction and pre‐S1 antigenemia in symptomatic and asymptomatic hepatitis B virus infections (1991) (32)
- Sarcoidosis and hepatitis C: clinical description of 11 cases (2010) (32)
- Heterogeneity of hepatitis B virus (HBV) core gene in a patient with HBV-associated cirrhosis and serum negativity for anti-HBc. (1996) (32)
- Lymphotropism of hepatitis B and C viruses: an update and a newcomer (1995) (32)
- Daclatasvir plus sofosbuvir with or without ribavirin in genotype 3 patients from a large French multicenter compassionate use program (2015) (32)
- [Early treatment of acute hepatitis C with interferon alpha-2b or interferon alpha-2b plus ribavirin: study of sixteen patients]. (2003) (32)
- In Vitro Characterization of the Anti-Hepatitis B Virus Activity and Cross-Resistance Profile of 2′,3′-Dideoxy-3′-Fluoroguanosine (2006) (32)
- Evolution and suppression of HBV strains with multidrug resistance to lamivudine, adefovir dipivoxil and entecavir in a patient with chronic hepatitis B (2010) (31)
- Adefovir dipivoxil resistance patterns in patients with lamivudine-resistant chronic hepatitis B (2009) (31)
- Association of Metabolic Risk Factors With Risks of Cancer and All‐Cause Mortality in Patients With Chronic Hepatitis B (2020) (31)
- Kinetics of intrahepatic covalently closed circular DNA and serum hepatitis B surface antigen during antiviral therapy for chronic hepatitis B: lessons from experimental and clinical studies. (2013) (31)
- Extrahepatic cancers are the leading cause of death in patients achieving hepatitis B virus control or hepatitis C virus eradication (2018) (30)
- Interferon-ribavirin in association with stavudine has no impact on plasma human immunodeficiency virus (HIV) type 1 level in patients coinfected with HIV and hepatitis C virus: a CORIST-ANRS HC1 trial. (2003) (30)
- LP28 : Efficacy of the oral sofosbuvir-based combinations in HCV genotype 4-mono-infected patients from the french observational cohort anrs CO22 hepather (2015) (30)
- Assessing hepatitis B virus resistance in vitro and molecular mechanisms of nucleoside resistance. (2002) (30)
- Boceprevir and telaprevir‐based triple therapy for chronic hepatitis C: virological efficacy and impact on kidney function and model for end‐stage liver disease score (2014) (30)
- Combination of nucleoside analogues in the treatment of chronic hepatitis B virus infection: lesson from experimental models. (2005) (29)
- Drug-resistant and immune-escape HBV mutants in HIV-infected hosts. (2010) (29)
- Predictors of hepatitis B surface antigen loss, relapse and retreatment after discontinuation of effective oral antiviral therapy in noncirrhotic HBeAg‐negative chronic hepatitis B (2020) (29)
- Hepatitis B surface antigen quantification as a predictor of seroclearance during treatment in HIV‐hepatitis B virus coinfected patients from Sub‐Saharan Africa (2016) (29)
- Modeling HIV-HCV coinfection epidemiology in the direct-acting antiviral era: the road to elimination (2017) (29)
- Cleaved c-FLIP mediates the antiviral effect of TNF-α against hepatitis B virus by dysregulating hepatocyte nuclear factors. (2016) (29)
- Chest CT for rapid triage of patients in multiple emergency departments during COVID-19 epidemic: experience report from a large French university hospital (2020) (28)
- Challenges to a Cure for HBV Infection (2017) (28)
- Validation of the INNO-LiPA HBV DR Assay (Version 2) in Monitoring Hepatitis B Virus-Infected Patients Receiving Nucleoside Analog Treatment (2010) (28)
- Covalently closed circular DNA: the ultimate therapeutic target for curing Hepatitis B virus infections. (2021) (28)
- Biological basis for functional cure of chronic hepatitis B (2019) (28)
- Current Management Strategies for Hepatitis B in the Elderly (2001) (28)
- Duck hepatitis B virus model in the study of hepatitis B virus. (2004) (27)
- A Preliminary Benefit-Risk Assessment of Lamivudine for the Treatment of Chronic Hepatitis B Virus Infection (2002) (27)
- Assessment of treatment efficacy in HBV infection and disease. (2006) (27)
- Ester prodrugs of acyclic nucleoside thiophosphonates compared to phosphonates: synthesis, antiviral activity and decomposition study. (2013) (27)
- How to improve access to therapy in hepatitis B patients (2018) (27)
- Comparison of the antiviral activity of adefovir and tenofovir on hepatitis B virus in HIV–HBV-coinfected patients (2008) (27)
- Probability of HBsAg loss after nucleo(s)tide analogue withdrawal depends on HBV genotype and viral antigen levels. (2022) (26)
- Microarray for Hepatitis B Virus Genotyping and Detection of 994 Mutations along the Genome (2010) (26)
- Proinflammatory cytokine TNF-α increases the stability of hepatitis B virus X protein through NF-κB signaling. (2011) (26)
- Hepatitis B virus Core protein nuclear interactome identifies SRSF10 as a host RNA-binding protein restricting HBV RNA production (2020) (25)
- Sulfur isotope analysis by MC-ICP-MS and application to small medical samples (2016) (25)
- Hepatitis C virus infection and B-cell non-Hodgkin's lymphoma: a cross-sectional study in Lyon, France (2004) (25)
- Safety and effectiveness of up to 3 years' bulevirtide monotherapy in patients with HDV-related cirrhosis. (2021) (25)
- New Antiviral Agents for the Therapy of Chronic Hepatitis B Virus Infection (1999) (25)
- Treatment of pre‐ and post‐liver transplantation HBV infection: Should we aim at combination therapy? (2003) (25)
- Hepatitis B Virus in Human Diseases (2016) (25)
- Hepatitis C virus infection propagates through interactions between Syndecan‐1 and CD81 and impacts the hepatocyte glycocalyx (2017) (25)
- Efficacy and tolerance of a combination of tenofovir disoproxil fumarate plus emtricitabine in patients with chronic hepatitis B: a European multicenter study. (2011) (25)
- Targeting innate immunity: a new step in the development of combination therapy for chronic hepatitis B. (2013) (25)
- DNA vaccination in combination or not with lamivudine treatment breaks humoral immune tolerance and enhances cccDNA clearance in the duck model of chronic hepatitis B virus infection. (2008) (24)
- Hepatitis B virus in tenofovir-naive Chinese patients with chronic hepatitis B contains no mutation of rtA194T conferring a reduced tenofovir susceptibility. (2009) (24)
- Similar evolution of hepatitis B virus quasispecies in patients with incomplete adefovir response receiving tenofovir/emtricitabine combination or tenofovir monotherapy. (2013) (24)
- Successful combination therapy of polyarteritis nodosa associated with a pre-core promoter mutant hepatitis B virus infection. (2001) (24)
- Efficacy and safety results of the phase 2 JNJ-56136379 JADE study in patients with chronic hepatitis B: Interim week 24 data (2020) (23)
- Standardized One-Step Real-Time Reverse Transcription-PCR Assay for Universal Detection and Quantification of Hepatitis Delta Virus from Clinical Samples in the Presence of a Heterologous Internal-Control RNA (2012) (23)
- HBV 2021: New therapeutic strategies against an old foe (2021) (23)
- Hepatitis B virus resistance to entecavir in nucleoside naïve patients: Does it exist? (2006) (22)
- Hepatitis B virus resistance to antivirals: clinical implications and management. (2003) (22)
- Nucleoside analogs in the treatment of chronic viral hepatitis. Efficiency and complications. (1994) (22)
- Diagnostic markers of viral hepatitis B and C. (1993) (22)
- Inhibition of hepatitis C virus replication by semi-synthetic derivatives of glycopeptide antibiotics (2010) (22)
- Rise in gamma interferon expression during resolution of duck hepatitis B virus infection. (2006) (21)
- Inhibitory effect of the combination of CpG-induced cytokines with lamivudine against hepatitis B virus replication in vitro (2009) (21)
- Pegylated Interferon α-2a Triggers NK-Cell Functionality and Specific T-Cell Responses in Patients with Chronic HBV Infection without HBsAg Seroconversion (2016) (21)
- An immortalized human liver endothelial sinusoidal cell line for the study of the pathobiology of the liver endothelium. (2014) (21)
- Low Risk of Lamivudine-Resistant HBV and Hepatic Fares in Treated HIV–HBV-Coinfected Patients from Côte d'Ivoire (2015) (21)
- Hepatitis B virus replication in primary macaque hepatocytes: Crossing the species barrier toward a new small primate model (2010) (21)
- The SATE pronucleotide approach applied to acyclovir: part II. Effects of bis(SATE)phosphotriester derivatives of acyclovir on duck hepatitis B virus replication in vitro and in vivo. (1999) (21)
- Animal models for the study of HBV infection and the evaluation of new anti‐HBV strategies (2002) (21)
- New approaches to the management of hepatitis C in haemophilia in 2012 (2012) (21)
- Hepatitis B virus wild‐type and rtN236T populations show similar early HBV DNA decline in adefovir refractory patients on a tenofovir‐based regimen (2013) (21)
- Initial amplification of duck hepatitis B virus covalently closed circular DNA after in vitro infection of embryonic duck hepatocytes is increased by cell cycle progression (2001) (20)
- Bridging basic science and clinical research: the EASL Monothematic Conference on Translational Research in Viral Hepatitis. (2014) (20)
- Hepatitis C virus infection in special groups. (1999) (20)
- Entecavir plus tenofovir combination therapy for chronic hepatitis B in patients with previous nucleos(t)ide treatment failure (2016) (19)
- Probable corticosteroid-induced reactivation of latent hepatitis B virus infection in an HIV-positive patient involving immune escape. (2012) (19)
- Association of anti‐E1E2 antibodies with spontaneous recovery or sustained viral response to therapy in patients infected with hepatitis C virus (2010) (19)
- Going towards more relevant cell culture models to study the in vitro replication of serum-derived hepatitis C virus and virus/host cell interactions? (2007) (19)
- Ribavirin restores IFNα responsiveness in HCV-infected livers by epigenetic remodelling at interferon stimulated genes (2015) (19)
- Short peptide nucleic acids (PNA) inhibit hepatitis C virus internal ribosome entry site (IRES) dependent translation in vitro. (2008) (19)
- Interplay between hepatitis B virus and TLR2-mediated innate immune responses: can restoration of TLR2 functions be a new therapeutic option? (2012) (19)
- Characterization of hepatitis B virus surface antigen variability and impact on HBs antigen clearance under nucleos(t)ide analogue therapy (2016) (19)
- Phytohemagglutinin and concanavalin A activate hepatitis B virus in peripheral blood mononuclear cells of patients with chronic hepatitis B virus infection (1992) (19)
- Quantification and epigenetic evaluation of the residual pool of hepatitis B covalently closed circular DNA in long-term nucleoside analogue-treated patients (2020) (18)
- HBV/HDV co‐infection in the Western Brazilian Amazonia: an intriguing mutation among HDV genotype 3 carriers (2014) (18)
- Antiviral Therapy in Patients with Hepatitis C Virus-Induced Cirrhosis (2015) (18)
- Hepatitis B virus infection enhances susceptibility toward adeno‐associated viral vector transduction in vitro and in vivo (2014) (18)
- Quantification of hepatitis B e antigen between Elecsys HBeAg and Architect HBeAg assays among patients infected with hepatitis B virus. (2013) (18)
- Hepatitis B virus mutation pattern rtL180M+A181C+M204V may contribute to entecavir resistance in clinical practice (2019) (18)
- Comparison between Elecsys HBsAg II and Architect HBsAg QT Assays for Quantification of Hepatitis B Surface Antigen among Patients Coinfected with HIV and Hepatitis B Virus (2011) (18)
- Is lamivudine effective on precore/core promoter mutants of hepatitis B virus? (2000) (18)
- Meeting the Challenge of Eliminating Chronic Hepatitis B Infection (2019) (18)
- 378 HEPATITIS B CORE (HBC) PROTEIN IS A KEY AND VERY EARLY NEGATIVE REGULATOR OF THE INTERFERON RESPONSE (2013) (18)
- Hepatitis B virus preS2Δ38–55 variants: A newly identified risk factor for hepatocellular carcinoma (2020) (17)
- Discontinuation of nucleos(t)ide analogues is not associated with a higher risk of HBsAg seroreversion after antiviral-induced HBsAg seroclearance: a nationwide multicentre study (2020) (17)
- Evaluation of novel strategies to combat hepatitis B virus targetting wild-type and drug-resistant mutants in experimental models. (2001) (17)
- Antiviral effect of a-glucosidase inhibitors on viral morphogenesis and binding properties of hepatitis C virus-like particles (2006) (17)
- Hepatitis B and hepatitis D virus infections in the Central African Republic, twenty-five years after a fulminant hepatitis outbreak, indicate continuing spread in asymptomatic young adults (2018) (17)
- Pathobiology of HBV mutants and clinical impact for treatment monitoring (2009) (17)
- A roadmap for serum biomarkers for hepatitis B virus: current status and future outlook (2022) (17)
- Clinical evaluation of the branched DNA assay for hepatitis B virus DNA detection in patients with chronic hepatitis B lacking hepatitis B e antigen and treated with interferon‐α (1998) (16)
- Selective detection of human hepatitis B virus surface and core antigens in peripheral blood mononuclear cell subsets by flow cytometry (1994) (16)
- Effect of mutating the two cysteines required for HBe antigenicity on hepatitis B virus DNA replication and virion secretion. (2005) (16)
- 2020 position statement and recommendations of the European Liver and Intestine Transplantation Association (ELITA): management of hepatitis B virus‐related infection before and after liver transplantation (2021) (16)
- Including Ratio of Platelets to Liver Stiffness Improves Accuracy of Screening for Esophageal Varices That Require Treatment. (2020) (16)
- Safety, pharmakokinetics and antiviral activity of novel capsid assembly modulator (CAM) JNJ-56136379 (JNJ-6379) in treatmentnaive chronic hepatitis B (CHB) patients without cirrhosis (2018) (16)
- Ethics and hepatitis B cure research (2016) (15)
- Ribavirin at the Era of Novel Direct Antiviral Agents for the Treatment of Hepatitis C Virus Infection: Relevance of Pharmacological Monitoring (2014) (15)
- Decreased infectivity of nucleoside analogs-resistant hepatitis B virus mutants. (2012) (15)
- Response‐guided and ‐unguided treatment of chronic hepatitis C (2012) (15)
- Preliminary Evidence for Hepatitis Delta Virus Exposure in Patients Who Are Apparently Not Infected With Hepatitis B Virus (2021) (15)
- Implementation of an in‐house quantitative real‐time polymerase chain reaction method for Hepatitis B virus quantification in West African countries (2016) (14)
- Non‐virological factors are drivers of hepatocellular carcinoma in virosuppressed hepatitis B cirrhosis: Results of ANRS CO12 CirVir cohort (2019) (14)
- Hepatitis: Treatment failure in chronic hepatitis B (2011) (14)
- Inhibition of hepatitis B virus gene expression: A step towards functional cure. (2017) (14)
- Evolution of glomerular filtration rate in HIV‐infected, HIV–HBV‐coinfected and HBV‐infected patients receiving tenofovir disoproxil fumarate (2013) (14)
- Iconography : Hépatite aiguë cytolytique induite par l'imatinib mesylate (2004) (14)
- Incremental value of HBcrAg to classify 1582 HBeAg‐negative individuals in chronic infection without liver disease or hepatitis (2021) (13)
- Detection of pre-S1 proteins in peripheral blood mononuclear cells from patients with HBV infection. (1991) (13)
- Factors associated with pandemic influenza A/H1N1 vaccine coverage in a French cohort of HIV-infected patients. (2011) (13)
- Adefovir dipivoxil is effective for the treatment of cirrhotic patients with lamivudine failure (2009) (13)
- Netrin-1 Protects Hepatocytes Against Cell Death Through Sustained Translation During the Unfolded Protein Response (2016) (13)
- Potent Inhibition of Late Stages of Hepadnavirus Replication by a Modified Cell Penetrating Peptide (2012) (13)
- Epidermal Growth Factor Receptor-Dependent Mutual Amplification between Netrin-1 and the Hepatitis C Virus (2016) (13)
- T‐ and B‐cell responses and previous exposure to hepatitis B virus in ‘anti‐HBc alone’ patients (2015) (13)
- Sexually transmitted HCV infection and reinfection in HIV-infected homosexual men. (2009) (13)
- Emerging drugs for hepatitis B (2007) (13)
- Novel Alpha Interferon (IFN-α) Variant with Improved Inhibitory Activity against Hepatitis C Virus Genotype 1 Replication Compared to IFN-α2b Therapy in a Subgenomic Replicon System (2006) (12)
- Tenofovir has inferior efficacy in adefovir-experienced chronic hepatitis B patients compared to nucleos(t)ide-naïve patients (2017) (12)
- Towards an improved and cost-saving prophylaxis of hepatitis B virus recurrence after liver transplantation? (2003) (12)
- Hepatitis B virus-specific T-cell reactivity during adefovir dipivoxil (ADV) treatment: A multicentre, controlled study (2002) (12)
- Interaction between Toll-Like Receptor 9-CpG Oligodeoxynucleotides and Hepatitis B Virus Virions Leads to Entry Inhibition in Hepatocytes and Reduction of Alpha Interferon Production by Plasmacytoid Dendritic Cells (2018) (12)
- Selective inhibition of the duck hepatitis B virus by a new class of tetraazamacrocycles (1997) (12)
- 366 PREVALENCE AND SEVERITY OF KIDNEY DYSFUNCTION IN PATIENTS WITH CHRONIC HEPATITIS B IN EUROPE: DATA FROM THE EUROPEAN VIRGIL COHORT (2011) (12)
- O112 : HBsAg clearance after addition of 48 weeks of pegifn in HBeAg negative CHB patients on nucleos(T)ide therapy with undetectable hbvdna for at least one year: final results from ANRS-HB06 pegan study: multicenter randomized controlled phase III trial (2015) (12)
- Perspectives on therapy of hepatitis B. (2003) (11)
- Role of a 48-week pegylated interferon therapy in hepatitis B e antigen positive HIV-co-infected patients on cART including tenofovir: EMVIPEG study. (2014) (11)
- Baseline interpatient hepatitis B viral diversity differentiates HBsAg outcomes in patients treated with tenofovir disoproxil fumarate. (2015) (11)
- In vivo electroporation improves therapeutic potency of a DNA vaccine targeting hepadnaviral proteins. (2012) (11)
- Inhibition of the binding of HCV serum particles to human hepatocytes by E1E2‐specific D32.10 monoclonal antibody (2009) (11)
- Synthesis of 5-haloethynyl- and 5-(1,2-dihalo)vinyluracil nucleosides: antiviral activity and cellular toxicity. (2005) (11)
- Enhanced magnitude and breadth of neutralizing humoral response to a DNA vaccine targeting the DHBV envelope protein delivered by in vivo electroporation. (2012) (11)
- BAY 41-4109-mediated aggregation of assembled and misassembled HBV capsids in cells revealed by electron microscopy. (2019) (11)
- Late hepatitis B reactivation following direct‐acting antiviral–based treatment of recurrent hepatitis C in an anti‐HBc–positive liver transplant recipient (2018) (10)
- Protein-Peptide Arrays for Detection of Specific Anti-Hepatitis D Virus (HDV) Genotype 1, 6, and 8 Antibodies among HDV-Infected Patients by Surface Plasmon Resonance Imaging (2015) (10)
- The life cycle of hepatitis B virus and antiviral targets (2011) (10)
- In vivo infectivity of liver extracts after resolution of hepadnaviral infection following therapy associating DNA vaccine and cytokine genes (2013) (10)
- Remodeling of B-Cell Subsets in Blood during Pegylated IFNα-2a Therapy in Patients with Chronic Hepatitis B Infection (2016) (10)
- Effects of liver growth factors on hepadnavirus replication in chronically infected duck hepatocytes. (2006) (9)
- HCV-Related Mortality Among HIV/HCV Co-infected Patients: The Importance of Behaviors in the HCV Cure Era (ANRS CO13 HEPAVIH Cohort) (2019) (9)
- Flares during long‐term entecavir therapy in chronic hepatitis B (2016) (9)
- P0795 : Safety and efficacy of sofosbuvir-containing regimens in the French observational cohort ANRS CO22 HEPATHER (2015) (9)
- Genetic vaccination for production of DNA-designed antibodies specific to Hepadnavirus envelope proteins. (2006) (9)
- Ultradeep Pyrosequencing and Molecular Modeling Identify Key Structural Features of Hepatitis B Virus RNase H, a Putative Target for Antiviral Intervention (2013) (9)
- ENTECAVIR AND TENOFOVIR COMBINATION THERAPY IN CHRONIC HEPATITIS B : RESCUE THERAPY IN PATIENTS WITH ADVANCED FIBROSIS AND MULTIPLE PREVIOUS TREATMENT FAILURES. RESULTS FROM AN INTERNATIONAL MULTICENTER COHORT STUDY (2009) (9)
- [Hepatitis C virus infection and thyroid diseases]. (1999) (9)
- Acyclic nucleoside thiophosphonates as potent inhibitors of HIV and HBV replication (2011) (9)
- Emerging drugs for hepatitis (2017) (8)
- Lower ribavirin biodisponibility in patients with HIV-HCV coinfection in comparison with HCV monoinfected patients (2014) (8)
- Non‐F HBV/HDV‐3 coinfection is associated with severe liver disease in Western Brazilian Amazon (2019) (8)
- [Imatinib mesylate-induced acute cytolytic hepatitis]. (2004) (8)
- Does occult HBV infection have an impact on the evolution of chronic hepatitis C? (2013) (8)
- Author Correction: Therapeutic strategies for hepatitis B virus infection: towards a cure (2020) (8)
- CRISPR-Cas9 Targeting of Hepatitis B Virus Covalently Closed Circular DNA Generates Transcriptionally Active Episomal Variants (2022) (8)
- A cyclic PNA-based compound targeting domain IV of HCV IRES RNA inhibits in vitro IRES-dependent translation. (2005) (8)
- Reciprocal antagonism between the netrin-1 receptor uncoordinated-phenotype-5A (UNC5A) and the hepatitis C virus (2017) (8)
- Predictive Factors for Hepatocellular Carcinoma in Chronic Hepatitis B Using Structural Equation Modeling: A Prospective Cohort Study. (2021) (8)
- Precore G1896A mutation is associated with reduced rates of HBsAg seroclearance in treated HIV hepatitis B virus co‐infected patients from Western Africa (2018) (8)
- Using Pharmacokinetic and Viral Kinetic Modeling To Estimate the Antiviral Effectiveness of Telaprevir, Boceprevir, and Pegylated Interferon during Triple Therapy in Treatment-Experienced Hepatitis C Virus-Infected Cirrhotic Patients (2014) (8)
- Early hepatocellular carcinoma detection using magnetic resonance imaging is cost-effective in high-risk patients with cirrhosis (2021) (8)
- Sofosbuvir plus daclatasvir with or without ribavirin for chronic hepatitis C infection: Impact of drug concentration on viral load decay. (2016) (8)
- Selective detection of human hepatitis B virus surface and core antigens in some peripheral blood mononuclear cell subsets by flow cytometry. (1992) (8)
- Early virological assessment during telaprevir- or boceprevir-based triple therapy in hepatitis C cirrhotic patients who failed a previous interferon based regimen - The ANRS CO20-CUPIC study. (2015) (8)
- Impact of deletions and mutations in Hepatitis B virus envelope proteins on serological profile and clinical evolution. (2017) (8)
- Retreatment with direct-acting antivirals of genotypes 1-3-4 hepatitis C patients who failed an anti-NS5A regimen in real world. (2017) (7)
- Impact of cirrhosis aetiology on incidence and prognosis of hepatocellular carcinoma diagnosed during surveillance (2021) (7)
- Preliminary evidence for hdv exposure in apparently non-HBV-infected patients. (2020) (7)
- Delta infection in chronic HBs Ag carriers in Tunisia: high prevalence in chronic asymptomatic HBs Ag carriers and in HBs Ag positive cirrhosis. (1990) (7)
- Two-dimensional-cultures of primary human hepatocytes allow efficient HBV infection: Old tricks still work! (2020) (7)
- Early detection of hepatitis B drug resistance: implications for patient management (2003) (7)
- P0535 : Direct antiviral effects of various pattern recognition receptor (PRR) agonists in HBV-replicating hepatocytes (2015) (7)
- Nomenclature of HBV core protein-targeting antivirals (2022) (7)
- Clinical Outcomes during Treatment Interruptions in Human Immunodeficiency Virus-Hepatitis B Virus Co-infected Patients from Sub-Saharan Africa. (2017) (7)
- Benefit of direct-acting antiviral therapy for hepatitis C virus (HCV) in monoinfected and HIV-HCV-coinfected patients with mixed cryoglobulinaemia. (2018) (7)
- 531 TENOFOVIR DF TREATMENT IS SAFE AND WELL TOLERATED IN CHRONIC HEPATITIS B (CHB) PATIENTS WITH BASELINE DECREASED GLOMERULAR FILTRATION RATE (2012) (7)
- Patient-reported symptoms during direct-acting antiviral treatment: A real-life study in HIV-HCV coinfected patients (ANRS CO13 HEPAVIH). (2020) (7)
- Impact of HBeAg on Hepatocellular Carcinoma Risk During Oral Antiviral Treatment in Patients with Chronic Hepatitis B. (2021) (7)
- Impact of IL28B, APOH and ITPA Polymorphisms on Efficacy and Safety of TVR- or BOC-Based Triple Therapy in Treatment-Experienced HCV-1 Patients with Compensated Cirrhosis from the ANRS CO20-CUPIC Study (2015) (6)
- New Recommendations of Baveno Vi Conference for the Screening of Portal Hypertension: An Independent Sequential Validation in Patients with Compensated Viral Cirrhosis Taking into Account Virological Status (Anrs Co12 Cirvir Cohort) (2016) (6)
- Hepatitis B virus genotype G and liver fibrosis progression in chronic hepatitis B and human immunodeficiency virus coinfection (2018) (6)
- PreS1 antigen/antibody patterns following interferon therapy in acute and chronic hepatitis B. (1994) (6)
- FIG4 is a hepatitis C virus particle-bound protein implicated in virion morphogenesis and infectivity with cholesteryl ester modulation potential. (2016) (6)
- Impact of lamivudine-resistance mutations on entecavir treatment outcome in hepatitis B (2014) (6)
- Quantification and genotyping in management of chronic hepatitis B and C. (2001) (6)
- Modelisation, synthesis and antiviral evaluation of new 2,3-disubstituted thiazolidinone nucleoside analogues (1996) (6)
- End points of therapy in chronic hepatitis B (2010) (6)
- Significance of serum HBV RNA in non‐cirrhotic HBeAg‐negative chronic hepatitis B patients who discontinue effective antiviral therapy (2022) (6)
- [Hepatitis B virus reactivation after allogeneic bone marrow transplantation in a patient previously cured of hepatitis B]. (1999) (6)
- P1061 LONG-TERM TREATMENT WITH TENOFOVIR IN TREATMENT-NAIVE OR -EXPERIENCED CHB PATIENTS IS EFFECTIVE AND WELL TOLERATED IN REAL-LIFE PRACTICE: 3 YEARS RESULTS OF THE VIREAL STUDY (2014) (6)
- Current and emerging therapeutic approaches to hepatitis C infection (2003) (6)
- CD81 large extracellular loop-containing fusion proteins with a dominant negative effect on HCV cell spread and replication. (2017) (5)
- Inducers of the NF-κB pathways impair hepatitis delta virus replication and strongly decrease progeny infectivity in vitro (2021) (5)
- 559 An overview of biochemical markers (fibrotest-actitest) diagnostic value in chronic liver diseases: A non-invasive alternative to liver biopsy (2003) (5)
- Design and evaluation of hepatitis B virus inhibitors. (2000) (5)
- [HBsAg quantification: virological significance]. (2010) (5)
- HIRA Supports Hepatitis B Virus Minichromosome Establishment and Transcriptional Activity in Infected Hepatocytes (2022) (5)
- Performance of the cobas® HBV RNA automated investigational assay for the detection and quantification of circulating HBV RNA in chronic HBV patients. (2022) (5)
- Treatment with tenofovir disoproxil fumarate or entecavir in chronic hepatitis B virus‐infected patients with renal impairment: results from a 7‐year, multicentre retrospective cohort study (2020) (5)
- Markedly effective local control of hepatocellular carcinoma with a poor prognosis by combined multimodal therapy with sorafenib as a neoadjuvant approach. (2010) (5)
- Hepatitis B Virus Genotype Study in West Africa Reveals an Expanding Clade of Subgenotype A4 (2021) (5)
- Low incidence of precore W28* mutant variants in treated hepatitis B virus and human immunodeficiency virus co-infected patients. (2018) (5)
- A 3-year follow-up study after treatment with simeprevir in combination with pegylated interferon-α and ribavirin for chronic hepatitis C virus infection (2018) (5)
- [Clinical and virological evaluation of the detection of pre-S1 and pre-S2 antigens in serum from patients with chronic hepatitis B]. (1995) (5)
- Benefit of direct-acting antiviral therapy in hepatitis C virus (HCV) monoinfected and HIV-HCV coinfected patients with mixed cryoglobulinemia (2017) (5)
- The variability of hepatitis B envelope is associated with HBs antigen persistence in either chronic or acute HBV genotype A infection. (2017) (5)
- Integrating genetic variants into clinical models for hepatocellular carcinoma risk stratification in cirrhosis. (2022) (5)
- [The prophylaxis of hepatocellular carcinoma by interferon-alpha in virus-induced cirrhosis]. (2000) (5)
- FRI-189-HBcrAg decline in JNJ-56136379-treated chronic hepatitis B patients: Results of a phase 1 study (2019) (5)
- Structure and Molecular Virology (2013) (5)
- Hepatic inflammation elicits production of proinflammatory netrin‐1 through exclusive activation of translation (2022) (5)
- Adefovir dipivoxil (ADV) for the treatment of patients with chronic hepatitis B (CHB) failing lamivudine (LAM) therapy (2003) (5)
- P0600 : Predictive factors of cirrhosis, hepatic decompensation and hepatocellular carcinoma in patients with chronic hepatitis delta (2015) (5)
- Subclinical and Clinical Outcomes in Patients Coinfected With HIV and Chronic Hepatitis B Virus From Clinical Outpatient Centers in France: Protocol for an Ambispective, Longitudinal Cohort Study (2020) (5)
- Possible prevention of chronic hepatitis B by early interferon therapy. (1990) (5)
- Assessing immunological and virological responses in the liver: Implications for the cure of chronic hepatitis B virus infection (2022) (5)
- Efficacy of daclatasvir-based quadruple therapy in nonresponder patients infected by hepatitis C virus genotype 4: the ANRS HC32 QUATTRO study (2017) (5)
- 934 EVOLUTION OF VIRAL LOAD AND GENOME SEQUENCE IN A CLINICAL TRIAL OF TENOFOVIR/EMTRICITABINE COMBINATION VERSUS TENOFOVIR MONOTHERAPY FOR PATIENTS WITH PREVIOUS ADEFOVIR DIPIVOXIL FAILURE (2009) (5)
- Safety and efficacy of the combination simeprevir-sofosbuvir in HCV genotype 1- and 4-mono-infected patients from the French ANRS CO22 hepather cohort (2019) (4)
- CD4+ T Cell Recovery and Hepatitis B Virus Coinfection in HIV-Infected Patients from Côte d'Ivoire Initiating Antiretroviral Therapy. (2018) (4)
- Retreatment with sofosbuvir plus grazoprevir plus elbasvir plus ribavirin of patients with Hepatitis C virus Genotype 1 or 4 with RASs at failure of a sofosbuvir plus ledipasvir or plus daclatasvir or plus simeprevir regimen (ANRS HC34 REVENGE study) (2017) (4)
- 11 IN VIVO RIBAVIRIN EFFECTS ON INTERFERON STIMULATED GENES TRANSCRIPTIONAL REGULATION INVOLVES CHROMATIN REMODELING AND HISTONE METHYLATION MEDIATED BY THE G9a METHYL-TRANSFERASE (2013) (4)
- 530 HIGH EFFICACY AND SAFETY OF TENOFOVIR DF IN 441 NAIVE AND NUC-EXPERIENCED CHRONIC HEPATITIS B PATIENTS: A REAL LIFE MULTICENTER PROSPECTIVE COHORT STUDY (2012) (4)
- Primary resistance of hepatitis B virus to nucleoside and nucleotide analogues (2018) (4)
- P0661 : Prediction of HBeAg seroconversion in HBeAg-positive chronic hepatitis B patients treated with entecavir using ALT and platelet count: Results from a large european multi-center study (2015) (4)
- Elevated coffee consumption is associated with a lower risk of elevated liver fibrosis biomarkers in patients treated for chronic hepatitis B (ANRS CO22 Hepather cohort). (2022) (4)
- Landscape of oncoviral genotype and co-infection via human papilloma and hepatitis B viral tumor in situ profiling (2021) (4)
- The scientific basis of combination therapy for chronic hepatitis B functional cure (2023) (4)
- Hepatitis B virus drug resistance: mechanism and clinical implications for the prevention of treatment failure (2006) (4)
- Inhibitory effect of penciclovir, the active metabolite of famciclovir, on the priming of hepadnavirus reverse transcription (1995) (4)
- Duck hepatitis B virus primary hepatocyte culture model. (2004) (4)
- Hepatitis B virus activity in untreated hepatitis B e antigen-negative human immunodeficiency virus-hepatitis B virus co-infected patients from sub-Saharan Africa. (2019) (4)
- Retraction statement: Disruption of cyclophilin D–mediated calcium transfer from the endoplasmic reticulum to mitochondria contributes to hepatic endoplasmic reticulum stress and insulin resistance (2013) (4)
- [Combination therapy in chronic hepatitis B]. (2008) (4)
- Sofosbuvir‐Daclatasvir is suboptimal in patients with genotype 2 chronic hepatitis C infection: real‐life experience from the HEPATHER ANRS CO22 cohort (2020) (4)
- Very late relapse of hepatitis C virus infection immediately after liver transplant (2018) (4)
- Baseline and Post-Treatment Hepatitis C NS5A Resistance in Relapsed Patients from a Multicentric Real-Life Cohort (2018) (4)
- Study of HBV replication capacity in relation to sequence variation in the precore and core promoter regions. (2004) (3)
- Hepatic steatosis and fibrosis despite metabolic differences in congenital hypo-cholesterolemia due to homozygous MTTP and APOB mutations (2014) (3)
- Development of hepatocellular carcinoma in chronic hepatitis B patients with advanced fibrosis is independent of viral genotype (2017) (3)
- 1020 SAFETY AND EFFICACY OF ENTECAVIR AND TENOFOVIR COMBINATION-THERAPY IN HEPATITIS B PATIENTS WITH PREVIOUS TREATMENT FAILURES. AN INTERNATIONAL MULTICENTER COHORT STUDY (2010) (3)
- Molecular Crosstalk between the Hepatitis C Virus and the Extracellular Matrix in Liver Fibrogenesis and Early Carcinogenesis (2021) (3)
- External validation of LCR1-LCR2, a multivariable HCC risk calculator, in patients with chronic HCV (2021) (3)
- Hepatocellular carcinoma-associated depletion of the netrin-1 receptor Uncoordinated Phenotype-5A (UNC5A) skews the hepatic unfolded protein response towards prosurvival outcomes. (2018) (3)
- Sofosbuvir plus ribavirin and sofosbuvir plus daclatasvir-based regimens are suboptimal in genotype 2 patients: real-life experience (2018) (3)
- Virus morphogenesis and viral entry as alternative targets for novel hepatitis C antivirals (2006) (3)
- Performance of the cobas® HBV RNA Automated Investigational Assay for the Detection and Quantification of Circulating HBV RNA in Chronic HBV Patients (2022) (3)
- Prospective Evidence That Hepatocellular Carcinoma Surveillance in Patients with Compensated Viral Cirrhosis Increases the Probability of Curative Treatment and Survival Taking into Account Lead-Time Bias (Anrs Co12 Cirvir Cohort) (2016) (3)
- A Model-Based Illustrative Exploratory Approach to Optimize the Dosing of Peg-IFN/RBV in Cirrhotic Hepatitis C Patients Treated With Triple Therapy (2014) (3)
- P0468 : Negative impact of HBV/HCV coinfection on HBV or HCV monoinfection: Data from the French cohort – ANRS CO22 hepather (2015) (3)
- [Study of the antiviral mechanism of action of ribavirin in the bovine viral diarrhea virus model]. (2002) (3)
- FRI-217-Safety, antiviral activity, and pharmacokinetics of a novel hepatitis B virus capsid assembly modulator, JNJ-, in Asian and non-Asian patients with chronic hepatitis B (2019) (3)
- Absence of impact of direct acting antivirals for hepatitis C virus on recurrent hepatocellular carcinoma tumor growth in the AFEF/ANRS CO22 Hepather cohort. (2020) (3)
- Effect of hepatitis B virus (HBV) surface‐gene variability on markers of replication during treated human immunodeficiency virus‐HBV infection in Western Africa (2018) (3)
- Viral hepatitis Elimination: Towards a hepatitis free world. (2022) (3)
- [Hepatitis B vaccine and liver cancer]. (2020) (3)
- Characterization of the Antiviral Effect of 2 9 ,3 9 -Dideoxy-2 9 , 3 9 -Didehydro- b - L -5-Fluorocytidine in the Duck Hepatitis B Virus Infection Model (1999) (3)
- 335 HBV INHIBITS THE AIM-2 INFLAMMASOME IN HUMAN KUPFFER CELLS (2013) (3)
- [Autoimmunization induced by interferon alpha therapy in chronic hepatitis C]. (2004) (3)
- Hepatitis B Virus Drug Resistance and Combination Therapy (2007) (3)
- [Favorable course of hepatitis B virus reactivation with hepatocellular insufficiency by a treatment combining corticoids, foscarnet and ganciclovir]. (1997) (3)
- Epidemiological, clinical, biological and virological factors influencing the occurrence of hepatocellular carcinoma and validation of predictive scores in 317 HBV-related cirrhotic patients. Prospective study Cir-B nested in the ANRS CO12 CirVir cohort (2016) (3)
- Direct-acting antivirals and viral RNA targeting for hepatitis B cure. (2020) (3)
- P0328 : Incidence, characteristics and determinants of primary liver cancer occurring during surveillance of compensated HCV cirrhosis according to sustained virological response (ANRS CO12 CirVir) (2015) (3)
- Higher risk of mortality in HIV-HBV co-infected patients from sub-Saharan Africa is observed at lower CD4+ cell counts (2021) (3)
- Liver capsule: Validated and potential novel targets to treat hepatitis B virus (2015) (2)
- Treatment of human immunodeficiency virus and hepatitis B virus infections (2012) (2)
- Identifying patients infected with hepatitis B virus in sub-Saharan Africa: potential for misclassification. (2015) (2)
- 38 Use of an improved hepatitis B virus recombinant baculovirus-HEPG2 system to study resistance to nucleoside analogs and the formation of CCCDNA (2006) (2)
- Viral hepatitis. (1999) (2)
- Correction: Sulfur isotope analysis by MC-ICP-MS and application to small medical samples (2016) (2)
- The Potential Implication of the Autonomic Nervous System in Hepatocellular Carcinoma (2019) (2)
- The way forward in HCV treatment — finding the right path (2008) (2)
- PreS antigen expression and anti-preS response in hepatitis B virus infections: relationship to serum HBV-DNA, intrahepatic HBcAg, liver damage and specific T-cell response. (1992) (2)
- [Prevention of liver fibrosis and liver cancer linked to hepatitis B virus in Africa: the Prolifica study]. (2019) (2)
- Antiviral therapy of chronic hepatitis (2017) (2)
- Gene Editing Technologies to Target HBV cccDNA (2022) (2)
- Interferon-free direct-acting antiviral therapy decreases the rate of hepatocellular carcinoma recurrence in patients with chronic hepatitis C and advanced fibrosis (2017) (2)
- 748 VIROLOGICAL RESPONSE AND TOLERANCE OF TENOFOVIR DF (TDF) IN THE ELDERLY IS SIMILAR TO YOUNGER PATIENTS IN REAL LIFE PRACTICE (2013) (2)
- Drug-resistant and immune-escape hepatitis B virus mutants in HIV-infected hosts (2010) (2)
- 10 Resistance surveillance of liver transplantation patients with lamivudine-resistant hepatitis B virus (HBV) after 96 weeks of adefovir dipivoxil treatment (2003) (2)
- Increased Ribavirin Bioavailability Associated With Telaprevir Use in Hepatitis C Patients Treated With PEGylated -Interferon/Ribavirin/Telaprevir Triple Therapy (2015) (2)
- Off-therapy cure of hepatitis delta after 3 years of bulevirtide monotherapy in a patient with compensated advanced cirrhosis (2022) (2)
- Methods for the Purification of Enzymatically Active Reverse Transcriptase of Duck Hepatitis B Virus (1994) (2)
- Diversity of Hepatocellular Carcinoma Clones Bearing Hematopoietic Malignancies‐Related Chromosomal Translocation (2014) (2)
- Droplet digital PCR quantitation of HBV cccDNA pool and transcriptional activity in long-term nucleos(t)ide analogue treated patients (2018) (2)
- 19 ANTIVIRAL EFFECT OF ENTECAVIR: RESULTS FROM 160 CHRONIC HEPATITIS B PATIENTS IN AN INTERNATIONAL MULTICENTER COHORT STUDY (2009) (2)
- LARP1 binding to hepatitis C virus particles is correlated with intracellular retention of viral infectivity. (2019) (2)
- Clinical outcomes after treatment with direct antiviral agents: beyond the virological response in patients with previous HCV-related decompensated cirrhosis (2021) (2)
- New anti-HCV agents in the pipeline (2014) (2)
- Rapid detection and further characterization of infection with hepatitis B virus variants containing a stop codon in the distal preC region (2007) (2)
- Correlation of serum hepatitis B core-related antigen with hepatitis B virus total intrahepatic DNA and covalently closed circular-DNA viral load in HIV–hepatitis B coinfection (2021) (2)
- Bulevirtide monotherapy for 48 Weeks in hdv patients with compensated cirrhosis and clinically significant portal hypertension. (2022) (2)
- [Definitions of resistance to analogue antiviral drugs in the treatment of chronic hepatitis B]. (2006) (2)
- Detection of pre-S1 antigen in PBMC and serum of anti-HBc-positive chronic HBs Ag carriers: A relevant tool for the decision of antiviral therapy (1989) (2)
- Real life study of bulevirtide in chronic hepatitis delta: preliminary results of the ANRS HD EP01 BuleDelta prospective cohort (2022) (2)
- 943 NOVEL GLUCOSIDASE INHIBITORS WITH ANTI-HBV AND ANTI-HCV ACTIVITY (2009) (2)
- HCV Eradication in Primary or Secondary Prevention Optimizes Hepatocellular Carcinoma Curative Management (2021) (2)
- Decay of Ccc-Dna is Slow and Marks Persistence of Intrahepatic Viral Dna Synthesis during Long-Term Tenofovir Treatment in Hiv-Hbv Co-Infected Patients (2016) (2)
- Heparanase is upregulated by HCV and favors its replication. (2022) (2)
- Viral quasispecies quantitative analysis: a novel approach for appraising the immune tolerant phase of chronic hepatitis B virus infection (2021) (1)
- Hepatitis B. (2018) (1)
- Early function modulation and reprogramming of Kupffer cells promote establishment and maintenance of HBV infection (2017) (1)
- Prevalence and Characterization of NS5A Resistance Associated Variants in Patients who Relapsed following Exposure to NS5A Inhibitors (2016) (1)
- 269 CHARACTERISATION OF PATHOGEN RECOGNITION RECEPTORS IN AN HEPATOCYTE CELL LINE (HEPARG CELLS) (2011) (1)
- HCV Virology (2021) (1)
- MECHANISMS OF HEPATITIS B VIRUS DRUG RESISTANCE (2009) (1)
- External Validation of LCR1-LCR2, a Multivariable Hepatocellular Carcinoma Risk Calculator, in a Multiethnic Cohort of Patients With Chronic Hepatitis B (2022) (1)
- [Current data on the treatment of chronic hepatitis B]. (2008) (1)
- Prediction of hepatocellular carcinoma in Hepatitis C patients with advanced fibrosis after sustained virologic response. (2022) (1)
- Glucosidase inhibitors induce HCV glycoproteins misfolding, impair viral assembly and release, and reduce the infectivity of residually secreted HCV particles (2006) (1)
- [Enzymatic amplification of sequences of viral nucleic acids. A methodological revolution promising new prospects in hepatology]. (1992) (1)
- External validation of the French AFP model for HCC liver transplantation in a recent unicentric cohort. (2021) (1)
- Simultaneous steroids/interferon therapy in chronic hepatitis B. (1993) (1)
- Viral Suppression is Not a risk Factor for CKD in Viral Cirrhosis (ANRS CO12 CirVir Prospective Cohort) (2016) (1)
- 31 – Virology and Pathogenesis of Hepatitis B (2018) (1)
- Anti-E1E2 antibodies do predict response to triple therapy in treatment-experienced Hepatitis C Virus-cirrhosis cases. (2015) (1)
- 681 INFECTIVITY PLAYS A MAJOR ROLE IN THE SELECTION OF HBV VARIANTS DURING ANTI-HBV THERAPY (2008) (1)
- Characterization of host and viral proteins involved in the chromatinization of the hepatitis B virus minichromosome (2018) (1)
- [Vaccination against hepatitis B virus: current data]. (1999) (1)
- Hepatitis B (2018) (1)
- 483 ONE-STEP REAL-TIME REVERSE TRANSCRIPTION-PCR ASSAY FOR UNIVERSAL QUANTIFICATION OF HEPATITIS DELTA VIRUS FROM CLINICAL SAMPLES IN THE PRESENCE OF A HETEROLOGOUS INTERNAL CONTROL RNA (2012) (1)
- 744 TREATMENT OF MULTIRESISTANT HBV PATIENTS WITH ENTECAVIR PLUS TENOFOVIR. 2 YEARS SAFETY AND EFFICACY ANALYSIS. AN INTERNATIONAL MULTICENTER COHORT STUDY (2011) (1)
- Management of Hepatitis B Virus (HBV) in transplantation. (2018) (1)
- Quantification of the hepatitis B virus cccDNA: evidence-based guidelines for monitoring the key obstacle of HBV cure (2023) (1)
- Targeting hepatitis B virus with CRISPR/Cas9 approach (2020) (1)
- Editorial overview: Antiviral strategies: Antiviral drug design: creating new ideas against old and new bugs (2017) (1)
- Clinical and virological features of chronic hepatitis B in the French national surveillance program, 2008–2012: A cross-sectional study (2022) (1)
- [Analogs combination therapy in chronic hepatitis B: when and how?]. (2010) (1)
- [Viral hepatitis]. (2015) (1)
- Durability of HBsAg loss with nucleotide analogs and pegylated interferon in patients infected with hepatitis B virus (2017) (1)
- Cost-effectiveness of scaling-up treatment with nucleoside analogue (NA) for chronic HBV infection: Towards a simplification of recommendations? (ANRS study) (2020) (1)
- Landscape of oncoviral genotype and co-infection via Human papilloma and Hepatitis B viral tumor in-situ profiling (2020) (1)
- Adefovir serum levels do not differ between responders and nonresponders (2011) (1)
- Inflammatory Gene Expression Associates with Hepatitis B Virus cccDNA- but Not Integrant-Derived Transcripts in HBeAg Negative Disease (2022) (1)
- Learning from HIV: how will drug resistance influence treatment strategies against hepatitis C? (2007) (1)
- Serum and intrahepatic HBV markers and HBV-specific CD8 T cell responses after nucleos(t)ide analog therapy discontinuation in HBeAg-negative chronic hepatitis B patients (2020) (1)
- P.161 Alpha-glucosidase inhibitors prevent the assembly and induce a reduction of HCV infectivity (2006) (1)
- Sustained virologic response (SVR) to direct-acting antiviral (DAA) therapy in patients with chronic hepatitis C virus (HCV) infection and hepatocellular carcinoma (HCC): a systematic review and meta-analysis (2018) (1)
- External validation of the French alpha‐fetoprotein model for hepatocellular carcinoma liver transplantation in a recent unicentric cohort – a retrospective study (2021) (1)
- O.168 Rolling circle amplification technology for the study of HBV variants (2006) (1)
- Development of a quantitative assay for hepatic HBV ccc DNA levels in patients with chronic hepatitis B (2002) (1)
- 916 BOCEPREVIR AND TELAPREVIR BASED TRIPLE THERAPY FOR CHRONIC HEPATITIS C: ON-TREATMENT EFFICACY AND IMPACT ON KIDNEY FUNCTION AND MELD SCORE (2013) (1)
- Kidney transplant and cryptic hepatitis (2009) (1)
- P.092 Phenoscript-HBV®: a high throughput phenotyping test to evaluate the drug susceptibility of HBV strains isolated from patients (2006) (1)
- Potential effect of lamivudine‐induced S gene mutations on liver‐related pathogenesis in hepatitis D virus infection (2017) (1)
- TRIPLE ANTIVIRAL WITH AMANTADINE THERAPY FOR IFN-RIBAVIRIN NON-RESPONDERS WITH RECURRENT POST-TRANSPLANTATION HEPATITIS C. (2004) (1)
- Can We Predict Sustained Virologic Response to Interferon α Therapy in Patients With Chronic Hepatitis Delta Virus Infection? (2015) (1)
- Cannabis use as a factor of lower corpulence in hepatitis C-infected patients: results from the ANRS CO22 Hepather cohort (2022) (1)
- Antiviral activity of famciclovir therapy on HBV replication in patients with chronic hepatitis B (1997) (1)
- Hepatitis B virus genome diversity in adolescents: Tenofovir disoproxil fumarate treatment effect and HBeAg serocon version (2021) (0)
- [Chronic hepatitis B: natural history and treatments]. (2002) (0)
- 793 HEPATITIS C VIRUS INDUCES ULTRASTRUCTURAL MODIFICATIONS IN DIFFERENTIATED HUH7.5 CELLS (2011) (0)
- A 3-Year Course Of Bulevirtide Monotherapy May Cure Hdv Infection In Cirrhotics. (2023) (0)
- Interest of echocardiography in the management of acute kidney injury in cirrhotic patients with ascites. Results of the prospective pilot cirren study (2020) (0)
- 15 CONTROL OF HBV REPLICATION BY HEPATOCYTES INNATE RESPONSE (2008) (0)
- Early intrahepatic recurrence of HBV infection in liver transplant recipients despite antiviral prophylaxis (2023) (0)
- 833 HCV-REPLICATING HEPG2 CELLS PRODUCE INFECTIOUS APO-E POSITIVE, BUT APO-B NEGATIVE HYBRID PARTICLES (2012) (0)
- 846 CHARACTERIZATION OF THE EARLY VIRAL KINETICS IN COMPENSATED CIRRHOTIC TREATMENT-EXPERIENCED PATIENTS TREATED WITH BOCEPREVIR AND TELAPREVIR (2013) (0)
- Economic Impact of European Liver and Intestine Transplantation Association (ELITA) Recommendations for Hepatitis B Prophylaxis After Liver Transplantation (2023) (0)
- A novel phenotypic assay for monitoring hepatitis B virus (HBV) drug resistance during antiviral treatment (2003) (0)
- Natural history of chronic hepatitis B (2005) (0)
- 126 INTERPLAY BETWEEN NETRIN-1 AND HCV REPLICATION IN VITRO AND IN PATIENTS WITH CHRONIC HEPATITIS C (2012) (0)
- SAT-186-Pathophysiological impact of HCV on mitochondrial composition and functions (2019) (0)
- Molecular Virology and Life Cycle of Hepatitis B Virus (2021) (0)
- Joint Workshop: EASL- ILC Viral Hepatitis Workshop (2015) (0)
- Rapid detection and clinical significance of mutations in the promoter and the pre-core region of hepatitis B virus genome (1998) (0)
- Efficiency of DNA vaccine in association with lamivudine for chronic hepatitis B therapy (2003) (0)
- Hepatocellular carcinoma (HCC) scoring system for the individualized prediction of liver cancer in 1080 HCV-related compensated cirrhosis included in the French multicenter prospective cohort ANRS CO12 CirVir (2015) (0)
- Effect of hepatitis B virus (HBV) S-gene variability on markers of replication during treated HIV-HBV infection in Western Africa (2019) (0)
- T-26 Long-term FU of patients with CHC treated with telaprevir in combination with PEG-IFN alfa-2a and RBV: Interim analysis of the EXTEND study (2011) (0)
- [Current knowledge on chronic hepatitis B therapy]. (2001) (0)
- P1166 FACTORS ASSOCIATED WITH HCV TREATMENT INITIATION IN DRUG USERS FOLLOWED IN A CARE CENTER FOR ADDICTS (2014) (0)
- HEPATITIS B FORUM NEXT STEPS IN TREATING PATIENTS WITH CHRONIC HEPATITIS B: CAN WE CURE THIS DISEASE? (2014) (0)
- 112 INCIDENCE AND PREDICTIVE FACTORS OF HEPATOCELLULAR CARCINOMA AND COMPLICATIONS IN HBV- OR HCV-RELATED COMPENSATED CIRRHOSIS. A MULTICENTER PROSPECTIVE COHORT IN 1653 PATIENTS (ANRS CO12 CirVir) (2013) (0)
- The Benefits of Virosuppression on Progression of Portal Hypertension in Patients with Compensated Viral Cirrhosis (ANRS CO12 CirVir Cohort) (2016) (0)
- Inhibitors of alpha glucosidases impair HCV pseudoparticles morphogenesis, prevent viral secretion and entry into hepatoma cells (2005) (0)
- Current hepatitis delta virus type 1 (HDV1) infections in central and eastern Turkey indicate a wide genetic diversity that is probably linked to different HDV1 origins (2012) (0)
- What is the impact of the decrease of hepatitis C virus incidence on the value of current prognostic models for hepatocellular carcinoma? (2020) (0)
- 70 HEPATITIS B AND DELTA IN BANGUI – CENTRAL AFRICAN REPUBLIC – 25 YEARS AFTER THE FIRST REPORTED HEPATITIS DELTA EPIDEMIC (2012) (0)
- 437 ANRS 12202: HEPATITIS B AND DELTA HEPATITIS IN CENTRAL AFRICAN REPUBLIC (CAR): VIROLOGICAL REASSESSMENT OF A FULMINANT HEPATITIS OUTBREAK OCCURRING IN THE MID EIGHTIES (2012) (0)
- Copper Isotope Evidence of Oxidative Stress–Induced Hepatic Breakdown and the Transition to Hepatocellular Carcinoma (2022) (0)
- 169 DIFFERENT PATTERN OF DECOMPENSATION IN ALCOHOLIC VERSUS NON-ALCOHOLIC LIVER CIRRHOSIS (2011) (0)
- Implications of Unc5A depletion for hepatocyte survival in chronic liver diseases upon induction of the unfolded protein response (2017) (0)
- Improved hepatitis delta virus genome characterization by single molecule full‐length genome sequencing combined with VIRiONT pipeline (2023) (0)
- New perspectives on development of curative strategies for chronic hepatitis B. (2023) (0)
- P1062 3-YEAR TREATMENT WITH TENOFOVIR IN REAL-LIFE IS EFFECTIVE AND WELL TOLERATED IN CHB PATIENTS, INCLUDING THE ELDERLY AND PATIENTS WITH COMORBIDITIES (2014) (0)
- Hepatocellular carcinoma hosts immature neurons and cholinergic tumors that correlate with adverse molecular features and outcomes (2022) (0)
- Divergent patterns of hbv-rna and hbcrag levels in untreated chronic hepatitis delta: a large european cross-sectional study (2022) (0)
- [Recovery of chronic hepatitis B- delta infection by zidovudine and recombinant interferon alpha combination therapy in a patient with Kaposi's sarcoma associated with HIV infection]. (1992) (0)
- 44 INDUCTION OF AN EARLY PATHOGEN RECOGNITION RECEPTOR EXPRESSION AND ANTIVIRAL CYTOKINE RESPONSE IN HUMAN HEPATOCYTES AFTER HEPATITIS B VIRUS INFECTION (2012) (0)
- P0412 : Netrin-1 protects against hepatocytic cell death upon UPR through sustained translation in an UNC5A/C-dependent fashion (2015) (0)
- Proteomic analysis of hepatitis B virus cccDNA-specific associated proteins identifies crucial regulators of viral transcription and RNA processing (2018) (0)
- The advent of several novel antiviral andimmune modulatory therapies for chronichepatitis B now necessitates a (2017) (0)
- 855 HEPATITIS C VIRUS INDUCED METABOLIC REPROGRAMMING AND PATHOLOGICAL CONSEQUENCES (2012) (0)
- P189 STUDYING RECIPROCAL VIRAL INTERPLAY BETWEEN HBV AND HDV IN CO-INFECTED HepaRG CELLS (2014) (0)
- Low HBcrAg and HBsAg levels identify patients most likely to achieve sustained response after nucleos(t)ide analogue cessation: results from a global individual patient data meta-analysis (create study) (2020) (0)
- CT ON CLINICAL MANAGEMENT (2009) (0)
- 29 Testing the antiviral activity of novel ribavirin derivatives and IFN alpha variants in the HCV replicon system (2004) (0)
- HEP-05-0036.R1 Susceptibility to Antivirals of an HBV Strain With Mutations Conferring Resistance to Both Lamivudine and Adefovir (2009) (0)
- P1262 : An accurate score for the prediction of sustained viral response under protease inhibitor-based triple therapy in cirrhotic patients: The cupic algorithm – the ANRS CO20 CUPIC study (2015) (0)
- [New virologic tests and their application in management of chronic hepatitis B]. (2006) (0)
- Identification of shuttle protein hnRNPA1 as a modulating factor of circulating hepatitis B Virus RNAs release in chronic hepatitis B patients (2022) (0)
- P0794 : Relationship between HCV genotype, liver co-morbidities and fibrosis in the French cohort ANRS CO22 HEPATHER (2015) (0)
- Clinical Aspects of Hepatitis C Virus Infection (2009) (0)
- 321 Hepatocellular Carcinoma in a Non-Cirrhotic Liver: Presentation of a Medico-Surgical Series of 40 Cases (2008) (0)
- P1081 VACCINE ESCAPE MUTANTS AND SUBOPTIMAL HEPATITIS B VIRUS RESPONSE IN HIV–HBV COINFECTED PATIENTS FROM SUB-SAHARAN AFRICA (2014) (0)
- Predictive factors of virological response at one year in patients with chronic HBV/HDV co-infected treated with Bulevirtide (2022) (0)
- P0314 PERSISTENCE OF HEPATITIS B INFECTION DESPITE A HIGH LEVEL OF HBS ANTIBODIES (2004) (0)
- 542 THE ENTEBE STUDY: SAFETY AND EFFICACY OF ENTECAVIR PLUS TENOFOVIR IN ADULTS WITH CHRONIC HEPATITIS B AND PREVIOUS NUCLEOS(T)IDE TREATMENT FAILURE (2012) (0)
- Hepatic inflammation upregulates netrin-1 in mice and in vitro through translational activation and transcript topology alteration in a LA-related protein-1 (LARP1)-dependent manner (2020) (0)
- Prevalence and characterization of NS5A resistance associated variants (RAVs) in patients who relapsed following exposure to NS5A inhibitors (2016) (0)
- [Clinical implications of interactions between hepatitis B virus and mononuclear leukocytes]. (1990) (0)
- [Treatment of hepatitis C]. (2005) (0)
- 762 ADDITIONAL PEG-INTERFERON IN HBeAg-POSITIVE HIV CO-INFECTED PATIENTS ON cART INCLUDING TENOFOVIR: THE ANRS HB01 EMVIPEG STUDY (2013) (0)
- O‐11: Dual function of RIG‐I RNA helicase as an innate sensor and as a direct antiviral effector during hepatitis B virus infection (2015) (0)
- P0579 : Epidemiological, clinical and virological features of hepatitis delta virus infection in France (2015) (0)
- 710 EVOLUTION OF GLOMERULAR FILTRATION RATE IN HIV-INFECTED, HIV-HBV COINFECTED AND HBV-INFECTED PATIENTS RECEIVING TENOFOVIR (2011) (0)
- Clinical and virological predictors of response after antiviral therapy interruption in HBeAg-negative chronic hepatitits B (2018) (0)
- Antiviral properties and liver specific delivery of a TLR1/2 ligand in HBV-infected in vitro and in vivo models (2018) (0)
- A 3-year follow-up study after treatment with simeprevir in combination with pegylated interferon-α and ribavirin for chronic hepatitis C virus infection (2018) (0)
- Table of contents (2016) (0)
- Hepatitis B virus-associated hepatocellular carcinoma is still a matter of concern in the French Caribbean Island of Guadeloupe. (2021) (0)
- Comprehensive immunophenotyping reveals profound alterations of T cell subsets in acute decompensation of liver cirrhosis (2022) (0)
- [Toward the expected development of therapeutic combinations in hepatitis B?]. (2002) (0)
- Long-Term Effectiveness, Safety, and Patient-Reported Outcomes of Self-Administered Subcutaneous Hepatitis B Immunoglobulin in Liver Post-Transplant Hepatitis B Prophylaxis: A Prospective Non-Interventional Study (2022) (0)
- P.158 Novel interferon alpha variant with improved inhibitory activity against HCV genotype 1 replication compared to IFN alpha-2b therapy, in a subgenomic replicon system (2006) (0)
- Hepatitis Delta virus in migrants: The challenge of elimination (ANRS CO22 HEPATHER cohort) (2021) (0)
- Virus-Infected Cirrhotic Patients in Treatment-Experienced Hepatitis C Pegylated Interferon during Triple Therapy Effectiveness of Telaprevir , Boceprevir , and Modeling To Estimate the Antiviral Using Pharmacokinetic and Viral Kinetic (2014) (0)
- Assessment of neutrophil subsets and immune checkpoint inhibitor expressions on T lymphocytes in liver transplantation: A preliminary study beyond the neutrophil-lymphocyte ratio (2023) (0)
- O.075 Evaluation of replication capacity and cross-resistance of HBV drug resistant mutants (2006) (0)
- [Treatment of hepatitis B: new perspectives]. (2009) (0)
- REVIEWS IN BASIC AND CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2014) (0)
- Adefovir treatment failure is not associated with low serum drug levels (2010) (0)
- off-treatment response is necessary to prevent both liver damage and the long-term complications of chronic hepatitis (2012) (0)
- 377 IMPLICATION OF CORE GENE IN HBV COVALENTLY CLOSED CIRCULAR DNA ACCUMULATION (2013) (0)
- Randomised phase 2 study (JADE) of the HBV capsid assembly modulator JNJ-56136379 with or without a nucleos(t)ide analogue in patients with chronic hepatitis B infection (2023) (0)
- P.028 No amplification of the hepatitis B virus covalently closed circular DNA after in vitro infection of the human hepatoma HepaRG cells (2006) (0)
- SAT-178 – International coalition to eliminate hepatitis B - progress report (2017) (0)
- CROSS RESISTANCE AND ITS IMPACT ON CLINICAL MANAGEMENT (2009) (0)
- A persistent HBV infection features spontaneous cccDNA loss and new rounds of infection (2022) (0)
- EASL recognition awardee 2013: Professor Yun-Fan Liaw. (2013) (0)
- 631 IFN-A/B TARGET GENES REPERTOIRES MODULATED BY EXOGENOUS TYPE I IFN AND BY THE ENDOGENOUS HBV-INDUCED IFN-RESPONSE IN LIVER CELLS (2010) (0)
- Direct antiviral properties of TLR ligands against HBV replication in immune-competent hepatocytes (2018) (0)
- Protein / peptide arrays to detect anti-Delta genotype 1 , 6 , 8 specific 1 antibodies among Hepatitis D Virus infected patients by surface plasmon 2 resonance imaging 3 4 (2015) (0)
- O50 THE SPECIFIC INFECTIVITY OF HEPATITIS C VIRUS IS REGULATED BY THE CATALYTIC ACTIVITY OF THE LIPID PEROXIDE SCAVENGER GLUTATHIONE PEROXIDASE 4 (2014) (0)
- [Experimental models for the study of hepadnaviruses and antiviral strategies]. (1995) (0)
- Infection Woodchuck Model of Hepatitis B Virus Delivery of Gamma Interferon in the Emtricitabine with Adenovirus-Mediated Effect of a Combination of Clevudine and (2004) (0)
- Prospective study of HBV cccDNA kinetics in a French multicenter cohort of liver transplant patients (ECOGREFFE) reveals very early graft infection despite NUC+HBIG prophylaxis (2020) (0)
- [New therapeutic advances in chronic hepatitis B]. (2003) (0)
- A novel population of immunosuppressive CD8 T cells is expanded in patients with decompensated liver disease (2017) (0)
- 108 HEPATITIS B VIRUS X PROTEIN IS REQUIRED FOR PRODUCTIVE INFECTION OF HUMAN HEPATOCYTES (2010) (0)
- Design, synthesis and structure relationships of new N,N',N",N"'-tetrakis (omega-amino alkyl) tetraazamacrocycles. (1998) (0)
- Sequence characterization of extracellular HBV RNA in patient plasma (2022) (0)
- [Treatment of hepatitis C: decisive therapeutic advances]. (2015) (0)
- P0553 : Polo-like-kinase 1, A positive effector in hepatitis B virus replication: Therapeutic implications (2015) (0)
- O211: With Interferon (2014) (0)
- O.165 Naturally occurring mutations that regulate hepatitis B e antigen expression (2006) (0)
- Christophe Mérieux Conference, Trends in Virology (2008) (0)
- Prognosis of alcoholic or viral B/C cirrhosis according to ABO blood group: results of abocirralvir, from CIRRAL and ANRS CO12 CirVir cohorts (2020) (0)
- The CUPIC algorithm: an accurate model for the prediction of sustained viral response under telaprevir or boceprevir triple therapy in cirrhotic patients (2015) (0)
- Iconographies supplémentaires de l'article : Hepatitis B virus: From diagnosis to treatment (2010) (0)
- Hepatitis D virus interferes with hepatitis B virus RNA production via interferon-dependent and -independent mechanisms. (2023) (0)
- Estimated risk reduction of mortality and transplantation with bezafibrate in patients with PBC and inadequate response to UDCA: application of the UK-PBC and Global PBC risk scores to the BEZURSO trial (2018) (0)
- [Towards new therapeutic concepts to fight against chronic hepatitis B]. (2016) (0)
- Modelization, Synthesis and Antiviral Evaluation of New 2,3‐ Disubstituted Thiazolidinone Nucleoside Analogues. (1996) (0)
- Deep sequencing analysis highlights variations associated with HBeAg seroconversion in adolescents with chronic hepatitis B (2018) (0)
- 680 HBV PHENOSCRIPT®: AN IN VITRO HIGH THROUGHPUT ASSAY FOR TESTING DRUG SUSCEPTIBILITY OF HBV STRAINS ISOLATED FROM PATIENTS (2008) (0)
- 765 TWELVE-MONTHS ENTECAVIR LONGITUDINAL CHANGES IN LIVER FIBROSIS, ACTIVITY AS PER FibroTest-FibroMax AND LIVER STIFFNESS MEASUREMENTS IN CHRONIC HEPATITIS B. STEATOSIS IMPACT ON FIBROSIS REGRESSION (2013) (0)
- Author Correction: Therapeutic strategies for hepatitis B virus infection: towards a cure (2020) (0)
- P.091 Selection and phenotypic characterization of multiple drug resistant variants in patients with chronic hepatitis B (2006) (0)
- Correlation of serum hepatitis B core-related antigen with HBV total intrahepatic DNA and ccc-DNA viral load in HIV-hepatitis B coinfection. (2020) (0)
- [Effects and risks of prolonged antiviral treatments: the example of chronic hepatitis B]. (1997) (0)
- Towards HBV Eradication: Future Perspective (2016) (0)
- Severe liver fibrosis in the HCV cure era: Major effects of social vulnerability, diabetes, and unhealthy behaviors (2022) (0)
- enofovir Is Effective Alone or With Emtricitabine in Adefovir-Treated atients With Chronic-Hepatitis B Virus Infection (0)
- 142 Drastic Inhibition of Late Stages of Hepadnavirus Morphogenesis by a Cell Penetrating Peptide (2009) (0)
- Favorable outcome in fulminating hepatitis associated with native anti-DNA antibodies. (1991) (0)
- 792 LIPOPROTEIN SECRETION PROFILES AND VLDL PRODUCTION IN HEPATOCYTE CELL LINES (2011) (0)
- THE ISPOPRENYLATED LARGE ISOFORM OF HEPATITIS DELTA VIRUS PROTEIN ACTIVATES STAT3 AND NF-ΚB , VIA OXIDATIVE STRESS (2012) (0)
- Occult HBV infections worsen the course of hepatitis infection (2002) (0)
- Cannabis Use Is Inversely Associated with Metabolic Disorders in Hepatitis C-Infected Patients (ANRS CO22 Hepather Cohort) (2022) (0)
- S2070 Prevalence of anti-HBs Antibody and Rate of HBV Vaccination Among Non HBV-Related Cirrhotic Patients (2008) (0)
- [Treatment of patients with chronic hepatitis C who relapsed or did not respond to a previous treatment]. (2002) (0)
- Heparanase-1: From Cancer Biology to a Future Antiviral Target (2023) (0)
- Therapeutic strategies for hepatitis B virus infection: towards a cure (2019) (0)
- 295 - Sustained Virologic Response (SVR) to Direct-Acting Antiviral (DAA) Therapy in Patients with Hepatitis C Virus (HCV) Infection and Hepatocellular Carcinoma (HCC): A Systematic Review and Meta-Analysis (2018) (0)
- Abstract 2130: Human papillomavirus and hepatitis B virus in situ tumor oncoviral genotype and coinfection drive oncogenesis and patient clinical response in cross cancer analysis (2020) (0)
- DEAD-box helicases DDX5 and DDX17 areinvolved in the fine tuning of hepatitis B virus minichromosome transcriptional regulation (2018) (0)
- OC-011 A novel population of immunosuppressive cd8 t cells is expanded in patients with decompensated liver disease (2017) (0)
- Naturally occurring hepatitis B virus core promoter mutants with extremely high replication capacity (2002) (0)
- An exceptional case of refractory variceal bleeding occurring during liver transplantation rescued with esophageal stent. (2021) (0)
- Screening of viral hepatitis and HIV among migrants from Southeast Asia (2018) (0)
- Predictors of HBsAg loss after cessation of nucleo (s)tide analogue therapy in asian patients with low HBsAg levels (2022) (0)
- Effectiveness and safety of bulevirtide monotherapy 2 mg/die in hdv patients with compensated cirrhosis and clinically significant portal hypertension (2022) (0)
- Reductions in Serum Hepatitis B Surface Antigen (HBsAg) Occur in Parallel with Reductions in Intrahepatic HBV Covalently Closed Circular (ccc) DNA in Chronic Hepatitis B (CH-B) Patients Receiving Adefovir Dipivoxil (ADV) (2004) (0)
- P.402 Occult hepatitis B virus infection in French patients with chronic hepatitis C (2006) (0)
- Translational Medicine in Hepatitis B Virus: What Can We Learn from Clinical Samples? (2016) (0)
- alpha-glucosidases inhibitors impair HCV pseudoparticles morphogenesis, prevent viral secretion and entry into hepatoma cells (2005) (0)
- Allosteric Modulators CTD C-terminal domain A alanine D aspartic acid WCE Whole Cell Extract MAPK Mitogen Activated Protein Kinase HTA Host Targeting Agent DAA Direct Acting Agent RNAi Ribonucleic Acid interference PIV 5 (2017) (0)
- Extrahepatic Cancer is the Second Cause of Non Liver-Related Death in Patients with Compensated Viral Cirrhosis and is Associated with Viral Replication (ANRS CO12 CirVir Prospective Cohort) (2016) (0)
- Characteristics of a new automated real time PCR assay for monitoring HBV patients (2006) (0)
- [Treatment of chronic viral hepatitis]. (1992) (0)
- Monitoring drug resistance in hepatitis B virus-infected patients during antiviral therapy: multi-center evaluation of the INNO-LiPA HBV-DR (2001) (0)
- Retreatment with Direct Active Antivirals of genotype 1, 3 and 4 chronic hepatitis C patients who previously failed an anti-NS5A-containing regimen in real world (2017) (0)
- P.012 Study of cccDNA formation and resistance to nucleoside analogs using an improved hepatitis B virus recombinant baculovirus-HepG2 system (2006) (0)
- Hepatitis C virus replication requires integrity of mitochondria-associated ER membranes (2022) (0)
- [Long-term treatment with lamivudine for chronic hepatitis B]. (2000) (0)
- Antiviral therapy of chronic hepatitis B virus infections: is resistance still a challenge? (2011) (0)
- O.104 Codelivery of cytokine genes with DNA vaccine to duck hepatitis B virus proteins improves its therapeutic efficacy (2006) (0)
- O107 ANTIVIRAL ACTIVITY OF VARIOUS INTERFERONS (IFNS) AND INFLAMMATORY CYTOKINES IN RELEVANT HEPATOCYTE MODELS OF PERSISTENT HEPATITIS B VIRUS (HBV) INFECTION (2014) (0)
- Genome-wide identification of direct HBx genomic targets (2017) (0)
- [Treatment of hepatitis B. Therapeutic management]. (2008) (0)
- 760 ENTECAVIR TREATMENT IS EFFECTIVE IN PATIENTS WITH PREVIOUS ADEFOVIR TREATMENT: RESULTS FROM AN INTERNATIONAL MULTICENTER COHORT STUDY (2011) (0)
- Identification of hepatitis B virus core protein nuclear interacting factors points to RNA binding proteins as major regulators of HBV replication (2018) (0)
- 446 IN VIVO ELECTROPORATION SIGNIFICANTLY IMPROVES THERAPEUTIC POTENCY OF A DNA VACCINE TARGETING HEPADNAVIRAL PROTEINS (2012) (0)
- P0768 : Late mortality in treatment-experienced cirrhotic patients treated with triple therapy including boceprevir or telaprevir in a real-life cohort - ANRS Co 20 cupic (2015) (0)
- Anti-E1E2 antibodies status prior therapy favors direct-acting antiviral treatment efficacy. (2018) (0)
- P0686 : Reciprocal antagonism between the uncoordinated phenotype-5A (UNC5A) dependence receptor and the hepatitis C virus (2015) (0)
- [Treatment of hepatitis C: decisive therapeutic advances]. (2020) (0)
- ANTIVIRAL RESISTANCE IN HBV (2009) (0)
- Comparison of the antiviral activity of Adefovir (ADV) and Teno- fovir (TDF) on hepatitis B virus (HBV) in HIV-HBV co-infected pa- tients. (2008) (0)
- New Antiviral Targets to Control Hepatitis B Virus Infection (2019) (0)
- New In Vitro Testing Systems for Hepatitis B and C Viruses (2007) (0)
- [Hepatitis delta: Clinical aspects and therapeutic perspectives]. (2017) (0)
- Innate responses CD 8 + cells B cells CD 4 + cells Adaptive immune responses Interferon alpha hNTCP Nucleos ( t ) ide analogues (2016) (0)
- 405 HARPE STUDY: PREVALENCE OF RENAL ABNORMALITIES IN CHRONIC HBV INFECTION (2013) (0)
- P.105 Final analysis of virological outcomes and resistance during 5 years of adefovir dipivoxil monotherapy in hepatitis B e antigen-negative patients (2006) (0)
- [Feedback from two French addiction centers and national survey on the intranasal naloxone (Nalscue®) in the prevention of opioid overdoses]. (2019) (0)
- [Hepatitis C virus]. (2000) (0)
- Characterization of circulating hepatitis B Virus RNAs in vitro and chronic hepatitis B patients (2022) (0)
- [Viral hepatitis]. (2020) (0)
- Hepatitis B, New Antiviral Targets (2020) (0)
- EFFICACY AND TOLERANCE OF TENOFOVIR DISOPROXIL FUMARATE PLUS EMTRICITABINE COMBINATION IN PATIENTS WITH CHRONIC HEPATITIS B - A EUROPEAN MULTICENTER STUDY (2010) (0)
- 1165 HCV INFECTION REPROGRAMS THE HEPATIC GLUCOSE AND GLUTAMINE METABOLISM (2013) (0)
- 16 TRANSITORY REPLICATION OF HCV (JFH1 STRAIN) IN HEPG2 AND HEPA-RG CELLS: CONTRIBUTION OF THE MODE OF GENOME DELIVERY AND MODULATION OF INNATE IMUNE RESPONSES (2008) (0)
- SAT-490-No impact of direct-acting antivirals on recurrent hepatocellular carcinoma tumour growth in the ANRS CO22 Hepather Cohort (2019) (0)
- Real Life Experience in Treating Chronic Hepatitis C with Direct Acting Antivirals: Genotyping and Subtype Matter (2016) (0)
- Eliminating cccDNA to cure Hepatitis B virus (HBV) infection. (2023) (0)
- A MICROARRAY FOR HEPATITIS B VIRUS GENOTYPING AND THE DETECTION 1 OF 994 MUTATIONS ALONG THE GENOME (2010) (0)
- Emerging anti-HDV drugs and HBV cure strategies with anti-HDV activity. (2023) (0)
- Molecular cross-talk between the hepatitis C virus and its microenvironment in liver fibrogenesis. (2017) (0)
- Interplay between hepatitis B virus and innate immune signaling pathways (2015) (0)
- 123 STRUCTURE OF THE HEPATITIS B VIRUS RNase H, A TARGET FOR NEW ANTIVIRAL DRUG DEVELOPMENT, UNRAVELED BY ULTRA-DEEP PYROSEQUENCING AND MOLECULAR MODELING (2013) (0)
- 458 N-GLYCOSYLATION MUTATIONS WITHIN HBSAG MAJOR HYDROPHILIC REGION CONTRIBUTE MOSTLY TO HEPATITIS B VIRUS IMMUNE ESCAPE MUTANT THROUGH ENHANCING VIRAL FITNESS (2012) (0)
- [794] WHAT IS THE ROLE OF HBV RTA181V/T MUTANTS IN HEPATITIS B TREATMENT FAILURE? (2007) (0)
- P.001 Characterization of occult HBV carriers according to a retrospective longitudinal follow-up of 26 patients (2006) (0)
- 453 Incidence and predictive factors of mutations in the YMDD motif of the HBV polymerase after two years of lamivudine treatment for chronic hepatitis B: Results of the prospective cohort lamivir (2004) (0)
- 496 GENOTYPIC RESISTANCE REDUCED TO VERY LOW LEVELS IN CHRONIC HEPATITIS B (CHB) PATIENTS TREATED OVER 2-YEARS WITH TELBIVUDINE (LDT) WHEN CONSIDERING BASELINE CHARACTERISTICS AND ROADMAP (2012) (0)
- [Significance of the expression of pre-S proteins in mononuclear blood cells in chronic hepatitis caused by the hepatitis B virus]. (1989) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Fabien Zoulim?
Fabien Zoulim is affiliated with the following schools:
